<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36364033</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1420-3049</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>21</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>25</Day></PubDate></JournalIssue><Title>Molecules (Basel, Switzerland)</Title><ISOAbbreviation>Molecules</ISOAbbreviation></Journal><ArticleTitle>Potential of Therapeutic Small Molecules in Apoptosis Regulation in the Treatment of Neurodegenerative Diseases: An Updated Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">7207</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/molecules27217207</ELocationID><Abstract><AbstractText>Neurodegenerative disorders (NDs) include Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) and the common feature of NDs is the progressive death of specific neurons in the brain. Apoptosis is very important in developing the nervous system, nonetheless an elevated level of cell death has been observed in the case of NDs. NDs are different in terms of their neuronal vulnerability and clinical manifestations, however they have some overlapping neurodegenerative pathways. It has been demonstrated by several studies with cell lines and animal models that apoptosis has a significant contribution to make in advancing AD, ALS, HD, and PD. Numerous dying neurons were also identified in the brains of individuals with NDs and these conditions were found to be linked with substantial cell loss along with common characteristics of apoptosis including activation of caspases and cysteine-proteases, DNA fragmentation, and chromatin condensation. It has been demonstrated that several therapeutic agents including antioxidants, minocycline, GAPDH ligands, p53 inhibitors, JNK (c-Jun N-Terminal Kinase) inhibitors, glycogen synthase kinase-3 inhibitor, non-steroidal anti-inflammatory drugs, D2 dopamine receptor agonists, FK506, cell cycle inhibitors, statins, drugs targeting peroxisome proliferator-activated receptors, and gene therapy have the potential to provide protection to neurons against apoptosis. Therefore, the use of these potential therapeutic agents might be beneficial in the treatment of NDs. In this review, we have summarized the pathways that are linked with apoptotic neuronal death in the case of various NDs. We have particularly focused on the therapeutic agents that have neuroprotective properties and the potential to regulate apoptosis in NDs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dailah</LastName><ForeName>Hamad Ghaleb</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Research and Scientific Studies Unit, College of Nursing, Jazan University, Jazan 45142, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RUP-5</GrantID><Agency>Deputyship for Research &amp;amp; Innovation, Ministry of Education in Saudi Arabia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Molecules</MedlineTA><NlmUniqueID>100964009</NlmUniqueID><ISSNLinking>1420-3049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D020169">Caspases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020169" MajorTopicYN="N">Caspases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DNA fragmentation</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">caspases</Keyword><Keyword MajorTopicYN="N">neurodegenerative disorders</Keyword><Keyword MajorTopicYN="N">neuronal death</Keyword><Keyword MajorTopicYN="N">neuroprotective drugs</Keyword></KeywordList><CoiStatement>The author declares no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36364033</ArticleId><ArticleId IdType="pmc">PMC9654492</ArticleId><ArticleId IdType="doi">10.3390/molecules27217207</ArticleId><ArticleId IdType="pii">molecules27217207</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muddapu V.R., Dharshini S.A.P., Chakravarthy V.S., Gromiha M.M. Neurodegenerative Diseases&#x2014;Is Metabolic Deficiency the Root Cause? Front. Neurosci. 2020;14:213. doi: 10.3389/fnins.2020.00213.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00213</ArticleId><ArticleId IdType="pmc">PMC7137637</ArticleId><ArticleId IdType="pubmed">32296300</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols E., Szoeke C.E.I., Vollset S.E., Abbasi N., Abd-Allah F., Abdela J., Aichour M.T.E., Akinyemi R.O., Alahdab F., Asgedom S.W., et al. Global, regional, and national burden of Alzheimer&#x2019;s disease and other dementias, 1990&#x2013;2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88&#x2013;106. doi: 10.1016/S1474-4422(18)30403-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30403-4</ArticleId><ArticleId IdType="pmc">PMC6291454</ArticleId><ArticleId IdType="pubmed">30497964</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S., Brayne C., Burns A., Cohen-Mansfield J., Cooper C., et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413&#x2013;446. doi: 10.1016/S0140-6736(20)30367-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30367-6</ArticleId><ArticleId IdType="pmc">PMC7392084</ArticleId><ArticleId IdType="pubmed">32738937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon J.R., Greenamyre J.T. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol. Sci. 2011;124:225&#x2013;250. doi: 10.1093/toxsci/kfr239.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/toxsci/kfr239</ArticleId><ArticleId IdType="pmc">PMC3216414</ArticleId><ArticleId IdType="pubmed">21914720</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo X., Castro-Obreg&#xf3;n S., Guti&#xe9;rrez-Becker B., Guti&#xe9;rrez-Ospina G., Karalis N., Khalil A.A., Lopez-Noguerola J.S., Rodr&#xed;guez L.L., Mart&#xed;nez-Mart&#xed;nez E., Perez-Cruz C., et al. Re-thinking the etiological framework of neurodegeneration. Front. Neurosci. 2019;13:728. doi: 10.3389/fnins.2019.00728.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00728</ArticleId><ArticleId IdType="pmc">PMC6667555</ArticleId><ArticleId IdType="pubmed">31396030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruttgen A., Saxena S., Evangelopoulos M.E., Weis J. Neurotrophins and Neurodegenerative Diseases: Receptors Stuck in Traffic? J. Neuropathol. Exp. Neurol. 2003;62:340&#x2013;350. doi: 10.1093/jnen/62.4.340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/62.4.340</ArticleId><ArticleId IdType="pubmed">12722826</ArticleId></ArticleIdList></Reference><Reference><Citation>Przedborski S., Vila M., Jackson-Lewis V. Series Introduction: Neurodegeneration: What is it and where are we? J. Clin. Investig. 2003;111:3. doi: 10.1172/JCI200317522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200317522</ArticleId><ArticleId IdType="pmc">PMC151843</ArticleId><ArticleId IdType="pubmed">12511579</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K.A. Basic mechanisms of neurodegeneration: A critical update. J. Cell. Mol. Med. 2010;14:457. doi: 10.1111/j.1582-4934.2010.01010.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2010.01010.x</ArticleId><ArticleId IdType="pmc">PMC3823450</ArticleId><ArticleId IdType="pubmed">20070435</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateos-Aparicio P., Rodr&#xed;guez-Moreno A. The Impact of Studying Brain Plasticity. Front. Cell. Neurosci. 2019;13:66. doi: 10.3389/fncel.2019.00066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00066</ArticleId><ArticleId IdType="pmc">PMC6400842</ArticleId><ArticleId IdType="pubmed">30873009</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorszewska J., Kozubski W., Waleszczyk W., Zabel M., Ong K. Neuroplasticity in the Pathology of Neurodegenerative Diseases. Neural Plast. 2020;2020 doi: 10.1155/2020/4245821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/4245821</ArticleId><ArticleId IdType="pmc">PMC7273406</ArticleId><ArticleId IdType="pubmed">32565775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilato F., Profice P., Ranieri F., Capone F., Di Iorio R., Florio L., Di Lazzaro V. Synaptic plasticity in neurodegenerative diseases evaluated and modulated by in vivo neurophysiological techniques. Mol. Neurobiol. 2012;46:563&#x2013;571. doi: 10.1007/s12035-012-8302-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8302-9</ArticleId><ArticleId IdType="pubmed">22821187</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu H.Y. Synaptic and cellular plasticity in Parkinson&#x2019;s disease. Acta Pharmacol. Sin. 2020;41:447&#x2013;452. doi: 10.1038/s41401-020-0371-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0371-0</ArticleId><ArticleId IdType="pmc">PMC7470833</ArticleId><ArticleId IdType="pubmed">32112041</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch E.E. Glutamatergic synaptic plasticity and dysfunction in Alzheimer disease: Emerging mechanisms. Neurology. 2018;91:125&#x2013;132. doi: 10.1212/WNL.0000000000005807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000005807</ArticleId><ArticleId IdType="pubmed">29898976</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Guo C., Kong J. Oxidative stress in neurodegenerative diseases. Neural Regen. Res. 2012;7:376. doi: 10.3969/J.ISSN.1673-5374.2012.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/J.ISSN.1673-5374.2012.05.009</ArticleId><ArticleId IdType="pmc">PMC4350122</ArticleId><ArticleId IdType="pubmed">25774178</ArticleId></ArticleIdList></Reference><Reference><Citation>Uttara B., Singh A., Zamboni P., Mahajan R. Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options. Curr. Neuropharmacol. 2009;7:65&#x2013;74. doi: 10.2174/157015909787602823.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157015909787602823</ArticleId><ArticleId IdType="pmc">PMC2724665</ArticleId><ArticleId IdType="pubmed">19721819</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Kukreti R., Saso L., Kukreti S. Oxidative stress: A key modulator in neurodegenerative diseases. Molecules. 2019;24:1583. doi: 10.3390/molecules24081583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24081583</ArticleId><ArticleId IdType="pmc">PMC6514564</ArticleId><ArticleId IdType="pubmed">31013638</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidatives stress. Nat. Rev. Drug Discov. 2004;3:205&#x2013;214. doi: 10.1038/nrd1330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1330</ArticleId><ArticleId IdType="pubmed">15031734</ArticleId></ArticleIdList></Reference><Reference><Citation>Misrani A., Tabassum S., Yang L. Mitochondrial Dysfunction and Oxidative Stress in Alzheimer&#x2019;s Disease. Front. Aging Neurosci. 2021;13:57. doi: 10.3389/fnagi.2021.617588.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2021.617588</ArticleId><ArticleId IdType="pmc">PMC7930231</ArticleId><ArticleId IdType="pubmed">33679375</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias V., Junn E., Mouradian M.M. The role of oxidative stress in parkinson&#x2019;s disease. J. Parkinsons. Dis. 2013;3:461&#x2013;491. doi: 10.3233/JPD-130230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-130230</ArticleId><ArticleId IdType="pmc">PMC4135313</ArticleId><ArticleId IdType="pubmed">24252804</ArticleId></ArticleIdList></Reference><Reference><Citation>Cunha-Oliveira T., Montezinho L., Mendes C., Firuzi O., Saso L., Oliveira P.J., Silva F.S.G. Oxidative Stress in Amyotrophic Lateral Sclerosis: Pathophysiology and Opportunities for Pharmacological Intervention. Oxid. Med. Cell. Longev. 2020;2020:5021694. doi: 10.1155/2020/5021694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/5021694</ArticleId><ArticleId IdType="pmc">PMC7683149</ArticleId><ArticleId IdType="pubmed">33274002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugalde C.L., Finkelstein D.I., Lawson V.A., Hill A.F. Pathogenic mechanisms of prion protein, amyloid-&#x3b2; and &#x3b1;-synuclein misfolding: The prion concept and neurotoxicity of protein oligomers. J. Neurochem. 2016;139:162&#x2013;180. doi: 10.1111/jnc.13772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13772</ArticleId><ArticleId IdType="pubmed">27529376</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker L., McAleese K.E., Thomas A.J., Johnson M., Martin-Ruiz C., Parker C., Colloby S.J., Jellinger K., Attems J. Neuropathologically mixed Alzheimer&#x2019;s and Lewy body disease: Burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129:729&#x2013;748. doi: 10.1007/s00401-015-1406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1406-3</ArticleId><ArticleId IdType="pubmed">25758940</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde T.E., Miller V.M. Proteinopathy-induced neuronal senescence: A hypothesis for brain failure in Alzheimer&#x2019;s and other neurodegenerative diseases. Alzheimers. Res. Ther. 2009;1:5. doi: 10.1186/alzrt5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt5</ArticleId><ArticleId IdType="pmc">PMC2874257</ArticleId><ArticleId IdType="pubmed">19822029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayer T.A. Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders? Eur. Neuropsychopharmacol. 2015;25:713&#x2013;724. doi: 10.1016/j.euroneuro.2013.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2013.03.007</ArticleId><ArticleId IdType="pubmed">23642796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciccocioppo F., Bologna G., Ercolino E., Pierdomenico L., Simeone P., Lanuti P., Pieragostino D., Del Boccio P., Marchisio M., Miscia S. Neurodegenerative diseases as proteinopathies-driven immune disorders. Neural Regen. Res. 2020;15:850&#x2013;856. doi: 10.4103/1673-5374.268971.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.268971</ArticleId><ArticleId IdType="pmc">PMC6990794</ArticleId><ArticleId IdType="pubmed">31719246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H.Y., Yang X. Proteases for Cell Suicide: Functions and Regulation of Caspases. Microbiol. Mol. Biol. Rev. 2000;64:821&#x2013;846. doi: 10.1128/MMBR.64.4.821-846.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.64.4.821-846.2000</ArticleId><ArticleId IdType="pmc">PMC99015</ArticleId><ArticleId IdType="pubmed">11104820</ArticleId></ArticleIdList></Reference><Reference><Citation>Martelli A.M., Zweyer M., Ochs R.L., Tazzari P.L., Tabellini G., Narducci P., Bortul R. Nuclear apoptotic changes: An overview. J. Cell. Biochem. 2001;82:634&#x2013;646. doi: 10.1002/jcb.1186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.1186</ArticleId><ArticleId IdType="pubmed">11500941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekshyyan O., Aw T. Apoptosis: A Key in Neurodegenerative Disorders. Curr. Neurovasc. Res. 2004;1:355&#x2013;371. doi: 10.2174/1567202043362018.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567202043362018</ArticleId><ArticleId IdType="pubmed">16181084</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro B.A., El-Deiry W.S. Targeting apoptosis in cancer therapy. Nat. Rev. Clin. Oncol. 2020;17:395&#x2013;417. doi: 10.1038/s41571-020-0341-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-020-0341-y</ArticleId><ArticleId IdType="pmc">PMC8211386</ArticleId><ArticleId IdType="pubmed">32203277</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh R., Letai A., Sarosiek K. Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat. Rev. Mol. Cell Biol. 2019;20:175&#x2013;193. doi: 10.1038/s41580-018-0089-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-018-0089-8</ArticleId><ArticleId IdType="pmc">PMC7325303</ArticleId><ArticleId IdType="pubmed">30655609</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Yankner B.A. Apoptosis in the nervous system. Nature. 2000;407:802&#x2013;809. doi: 10.1038/35037739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35037739</ArticleId><ArticleId IdType="pubmed">11048732</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J. Neuronal cell death in nervous system development, disease, and injury (Review) Int. J. Mol. Med. 2001;7:455&#x2013;478. doi: 10.3892/ijmm.7.5.455.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.7.5.455</ArticleId><ArticleId IdType="pubmed">11295106</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing C., Arai K., Lo E.H., Hommel M. Pathophysiologic cascades in ischemic stroke. Int. J. Stroke. 2012;7:378&#x2013;385. doi: 10.1111/j.1747-4949.2012.00839.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1747-4949.2012.00839.x</ArticleId><ArticleId IdType="pmc">PMC3985770</ArticleId><ArticleId IdType="pubmed">22712739</ArticleId></ArticleIdList></Reference><Reference><Citation>Belov Kirdajova D., Kriska J., Tureckova J., Anderova M. Ischemia-Triggered Glutamate Excitotoxicity from the Perspective of Glial Cells. Front. Cell. Neurosci. 2020;14:51. doi: 10.3389/fncel.2020.00051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00051</ArticleId><ArticleId IdType="pmc">PMC7098326</ArticleId><ArticleId IdType="pubmed">32265656</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedlander R.M. Apoptosis and Caspases in Neurodegenerative Diseases. N. Engl. J. Med. 2003;348:1365&#x2013;1375. doi: 10.1056/NEJMra022366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra022366</ArticleId><ArticleId IdType="pubmed">12672865</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobrido-Came&#xe1;n D., Barreiro-Iglesias A. Role of Caspase-8 and Fas in Cell Death After Spinal Cord Injury. Front. Mol. Neurosci. 2018;11:101. doi: 10.3389/fnmol.2018.00101.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00101</ArticleId><ArticleId IdType="pmc">PMC5891576</ArticleId><ArticleId IdType="pubmed">29666570</ArticleId></ArticleIdList></Reference><Reference><Citation>Deigner H.P., Haberkorn U., Kinscherf R. Apoptosis modulators in the therapy of neurodegenerative diseases. Expert Opin. Investig. Drugs. 2000;9:747&#x2013;764. doi: 10.1517/13543784.9.4.747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.9.4.747</ArticleId><ArticleId IdType="pubmed">11060707</ArticleId></ArticleIdList></Reference><Reference><Citation>Linsley J.W., Reisine T., Finkbeiner S. Cell death assays for neurodegenerative disease drug discovery. Expert Opin. Drug Discov. 2019;14:901&#x2013;913. doi: 10.1080/17460441.2019.1623784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2019.1623784</ArticleId><ArticleId IdType="pmc">PMC6663635</ArticleId><ArticleId IdType="pubmed">31179783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J., Zhao S., Li Y., Zhang D., Wang B., Xie J., Wang J. Regulated cell death: Discovery, features and implications for neurodegenerative diseases. Cell Commun. Signal. 2021;19:120. doi: 10.1186/s12964-021-00799-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-021-00799-8</ArticleId><ArticleId IdType="pmc">PMC8684172</ArticleId><ArticleId IdType="pubmed">34922574</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Q., Zhu X., Si J. Angelica polysaccharide ameliorates memory impairment in Alzheimer&#x2019;s disease rat through activating BDNF/TrkB/CREB pathway. Exp. Biol. Med. 2020;245:1&#x2013;10. doi: 10.1177/1535370219894558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370219894558</ArticleId><ArticleId IdType="pmc">PMC6987749</ArticleId><ArticleId IdType="pubmed">31847588</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.J., Kim S.H., Park Y., Park J., Lee J.H., Kim B.C., Song W.K. miR-16-5p is upregulated by amyloid &#x3b2; deposition in Alzheimer&#x2019;s disease models and induces neuronal cell apoptosis through direct targeting and suppression of BCL-2. Exp. Gerontol. 2020;136:110954. doi: 10.1016/j.exger.2020.110954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2020.110954</ArticleId><ArticleId IdType="pubmed">32320719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Pu Z., Li M., Wang K., Deng L., Chen W. Antioxidative and antiapoptosis: Neuroprotective effects of dauricine in Alzheimer&#x2019;s disease models. Life Sci. 2020;243:117237. doi: 10.1016/j.lfs.2019.117237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2019.117237</ArticleId><ArticleId IdType="pubmed">31887302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Hu S., Tuerdi M., Yu X., Zhang H., Zhou Y., Cao J., Da Silva Vaz I., Zhou J. Initiator and executioner caspases in salivary gland apoptosis of Rhipicephalus haemaphysaloides. Parasites Vectors. 2020;13:288. doi: 10.1186/s13071-020-04164-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13071-020-04164-5</ArticleId><ArticleId IdType="pmc">PMC7275347</ArticleId><ArticleId IdType="pubmed">32503655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P. Pathways towards and away from Alzheimer&#x2019;s disease. Nature. 2004;430:631&#x2013;639. doi: 10.1038/nature02621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02621</ArticleId><ArticleId IdType="pmc">PMC3091392</ArticleId><ArticleId IdType="pubmed">15295589</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J. Alzheimer&#x2019;s disease: Genes, proteins, and therapy. Physiol. Rev. 2001;81:741&#x2013;766. doi: 10.1152/physrev.2001.81.2.741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.2001.81.2.741</ArticleId><ArticleId IdType="pubmed">11274343</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I., Mattson M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer&#x2019;s disease. Trends Neurosci. 2008;31:454&#x2013;463. doi: 10.1016/j.tins.2008.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2008.06.005</ArticleId><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Green K.N., LaFerla F.M. Linking Calcium to A&#x3b2; and Alzheimer&#x2019;s Disease. Neuron. 2008;59:190&#x2013;194. doi: 10.1016/j.neuron.2008.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.07.013</ArticleId><ArticleId IdType="pubmed">18667147</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P. Calcium and neurodegeneration. Aging Cell. 2007;6:337&#x2013;350. doi: 10.1111/j.1474-9726.2007.00275.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2007.00275.x</ArticleId><ArticleId IdType="pubmed">17328689</ArticleId></ArticleIdList></Reference><Reference><Citation>Erekat N.S. Apoptosis and its Role in Parkinson&#x2019;s Disease. Park. Dis. Pathog. Clin. Asp. 2018:65&#x2013;82. doi: 10.15586/codonpublications.parkinsonsdisease.2018.ch4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15586/codonpublications.parkinsonsdisease.2018.ch4</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J., Gao S.S., Yang H.J., Wang M., Cheng B.F., Feng Z.W., Wang L. Neuroprotective effects of proanthocyanidins, natural flavonoids derived from plants, on rotenone-induced oxidative stress and apoptotic cell death in human neuroblastoma SH-SY5Y cells. Front. Neurosci. 2018;12:369. doi: 10.3389/fnins.2018.00369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00369</ArticleId><ArticleId IdType="pmc">PMC5990600</ArticleId><ArticleId IdType="pubmed">29904339</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan R., Vijayraja D., Mohankumar T., Manimaran D., Ganesan P., Choi D.K., Elangovan N. Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson&#x2019;s disease. J. Chem. Neuroanat. 2021;112:101890. doi: 10.1016/j.jchemneu.2020.101890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchemneu.2020.101890</ArticleId><ArticleId IdType="pubmed">33220427</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W., Luo B., Qiu C., Jiang X., Shen B., Zhang L., Liu W., Zhang W. TRIM3 attenuates apoptosis in Parkinson&#x2019;s disease via activating PI3K/AKT signal pathway. Aging. 2021;13:735&#x2013;749. doi: 10.18632/aging.202181.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.202181</ArticleId><ArticleId IdType="pmc">PMC7835008</ArticleId><ArticleId IdType="pubmed">33253119</ArticleId></ArticleIdList></Reference><Reference><Citation>Moujalled D., Strasser A., Liddell J.R. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28:2029&#x2013;2044. doi: 10.1038/s41418-021-00814-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-021-00814-y</ArticleId><ArticleId IdType="pmc">PMC8257776</ArticleId><ArticleId IdType="pubmed">34099897</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas B., Flint Beal M. Parkinson&#x2019;s disease. Hum. Mol. Genet. 2007;16:R183&#x2013;R194. doi: 10.1093/hmg/ddm159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm159</ArticleId><ArticleId IdType="pubmed">17911161</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallett P.J., Standaert D.G. Rationale for and use of NMDA receptor antagonists in Parkinson&#x2019;s disease. Pharmacol. Ther. 2004;102:155&#x2013;174. doi: 10.1016/j.pharmthera.2004.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2004.04.001</ArticleId><ArticleId IdType="pubmed">15163596</ArticleId></ArticleIdList></Reference><Reference><Citation>Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson&#x2019;s disease. Lancet Neurol. 2007;6:933&#x2013;938. doi: 10.1016/S1474-4422(07)70246-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(07)70246-6</ArticleId><ArticleId IdType="pubmed">17884683</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy S., Shannon K.M., Kordower J.H. Huntington&#x2019;s disease: Pathological mechanisms and therapeutic strategies. Cell Transplant. 2007;16:301&#x2013;312. doi: 10.3727/000000007783464687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/000000007783464687</ArticleId><ArticleId IdType="pubmed">17503740</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K., Aminoff M.J. Huntington&#x2019;s disease: Clinical characteristics, pathogenesis and therapies. Drugs Today. 2007;43:97&#x2013;116. doi: 10.1358/dot.2007.43.2.1050788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dot.2007.43.2.1050788</ArticleId><ArticleId IdType="pubmed">17353947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan M.M.Y., Raymond L.A. N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington&#x2019;s disease. Prog. Neurobiol. 2007;81:272&#x2013;293. doi: 10.1016/j.pneurobio.2006.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2006.11.003</ArticleId><ArticleId IdType="pubmed">17188796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington&#x2019;s disease. Subcell. Biochem. 2012;45:323&#x2013;335. doi: 10.1007/978-1-4020-6191-2_11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4020-6191-2_11</ArticleId><ArticleId IdType="pubmed">18193642</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji E.-S., Kim Y.-M., Shin M.-S., Kim C.-J., Lee K.-S., Kim K., Ha J., Chung Y.-R. Treadmill exercise enhances spatial learning ability through suppressing hippocampal apoptosis in Huntington&#x2019;s disease rats. J. Exerc. Rehabil. 2015;11:133&#x2013;139. doi: 10.12965/jer.150212.</Citation><ArticleIdList><ArticleId IdType="doi">10.12965/jer.150212</ArticleId><ArticleId IdType="pmc">PMC4492422</ArticleId><ArticleId IdType="pubmed">26171378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J., Kesavapany S., Pant H.C. The Pathobiology of Amyotrophic Lateral Sclerosis: A Proteinopathy? J. Neuropathol. Exp. Neurol. 2005;64:649&#x2013;664. doi: 10.1097/01.jnen.0000173889.71434.ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.jnen.0000173889.71434.ea</ArticleId><ArticleId IdType="pubmed">16106213</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Lewinski F., Keller B.U. Ca2+, mitochondria and selective motoneuron vulnerability: Implications for ALS. Trends Neurosci. 2005;28:494&#x2013;500. doi: 10.1016/j.tins.2005.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2005.07.001</ArticleId><ArticleId IdType="pubmed">16026864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoe T., Wanaka A., Nikaido T., Kanazawa K.Y., Shimizu J., Imaizumi K., Kanazawa I. Upregulation of the pro-apoptotic BH3-only peptide harakiri in spinal neurons of amyotrophic lateral sclerosis patients. Neurosci. Lett. 2001;313:153&#x2013;157. doi: 10.1016/S0304-3940(01)02250-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)02250-9</ArticleId><ArticleId IdType="pubmed">11682150</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel B.P., Safdar A., Raha S., Tarnopolsky M.A., Hamadeh M.J. Caloric restriction shortens lifespan through an increase in lipid peroxidation, inflammation and apoptosis in the G93A mouse, an animal model of ALS. PLoS ONE. 2010;5:e9386. doi: 10.1371/journal.pone.0009386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009386</ArticleId><ArticleId IdType="pmc">PMC2827549</ArticleId><ArticleId IdType="pubmed">20195368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaz A.R., Cunha C., Gomes C., Schmucki N., Barbosa M., Brites D. Glycoursodeoxycholic Acid Reduces Matrix Metalloproteinase-9 and Caspase-9 Activation in a Cellular Model of Superoxide Dismutase-1 Neurodegeneration. Mol. Neurobiol. 2015;51:864&#x2013;877. doi: 10.1007/s12035-014-8731-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-014-8731-8</ArticleId><ArticleId IdType="pubmed">24848512</ArticleId></ArticleIdList></Reference><Reference><Citation>Micheau O., Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114:181&#x2013;190. doi: 10.1016/S0092-8674(03)00521-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00521-X</ArticleId><ArticleId IdType="pubmed">12887920</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase G., Pettmann B., Raoul C., Henderson C.E. Signaling by death receptors in the nervous system. Curr. Opin. Neurobiol. 2008;18:284&#x2013;291. doi: 10.1016/j.conb.2008.07.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2008.07.013</ArticleId><ArticleId IdType="pmc">PMC2668142</ArticleId><ArticleId IdType="pubmed">18725296</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison D.C., Davis R.P., Bond B.C., Campbell C.A., James M.F., Parsons A.A., Philpott K.L. Caspase mRNA expression in a rat model of focal cerebral ischemia. Mol. Brain Res. 2001;89:133&#x2013;146. doi: 10.1016/S0169-328X(01)00058-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0169-328X(01)00058-4</ArticleId><ArticleId IdType="pubmed">11311984</ArticleId></ArticleIdList></Reference><Reference><Citation>Henshall D.C., Bonislawski D.P., Skradski S.L., Lan J.Q., Meller R., Simon R.P. Cleavage of Bid may amplify caspase-8-induced neuronal death following focally evoked limbic seizures. Neurobiol. Dis. 2001;8:568&#x2013;580. doi: 10.1006/nbdi.2001.0415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0415</ArticleId><ArticleId IdType="pubmed">11493022</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Lu C., Xia Z., Xiao B., Luo Y. Inhibition of caspase-8 attenuates neuronal death induced by limbic seizures in a cytochrome c-dependent and Smac/DIABLO-independent way. Brain Res. 2006;1098:204&#x2013;211. doi: 10.1016/j.brainres.2006.04.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.04.131</ArticleId><ArticleId IdType="pubmed">16774749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaiser W.J., Upton J.W., Long A.B., Livingston-Rosanoff D., Daley-Bauer L.P., Hakem R., Caspary T., Mocarski E.S. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471:368&#x2013;373. doi: 10.1038/nature09857.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09857</ArticleId><ArticleId IdType="pmc">PMC3060292</ArticleId><ArticleId IdType="pubmed">21368762</ArticleId></ArticleIdList></Reference><Reference><Citation>Oberst A., Dillon C.P., Weinlich R., McCormick L.L., Fitzgerald P., Pop C., Hakem R., Salvesen G.S., Green D.R. Catalytic activity of the caspase-8-FLIP L complex inhibits RIPK3-dependent necrosis. Nature. 2011;471:363&#x2013;368. doi: 10.1038/nature09852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09852</ArticleId><ArticleId IdType="pmc">PMC3077893</ArticleId><ArticleId IdType="pubmed">21368763</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Zhou X., McQuade T., Li J., Chan F.K.M., Zhang J. Functional complementation between FADD and RIP1 in embryos and lymphocytes. Nature. 2011;471:373&#x2013;377. doi: 10.1038/nature09878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09878</ArticleId><ArticleId IdType="pmc">PMC3072026</ArticleId><ArticleId IdType="pubmed">21368761</ArticleId></ArticleIdList></Reference><Reference><Citation>Krajewska M., You Z., Rong J., Kress C., Huang X., Yang J., Kyoda T., Leyva R., Banares S., Hu Y., et al. Neuronal deletion of caspase 8 protects against brain injury in mouse models of controlled cortical impact and kainic acid-induced excitotoxicity. PLoS ONE. 2011;6:e24341. doi: 10.1371/journal.pone.0024341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024341</ArticleId><ArticleId IdType="pmc">PMC3174961</ArticleId><ArticleId IdType="pubmed">21957448</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng E.H.Y., Wei M.C., Weiler S., Flavell R.A., Mak T.W., Lindsten T., Korsmeyer S.J. BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell. 2001;8:705&#x2013;711. doi: 10.1016/S1097-2765(01)00320-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(01)00320-3</ArticleId><ArticleId IdType="pubmed">11583631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M.C., Zong W.X., Cheng E.H.Y., Lindsten T., Panoutsakopoulou V., Ross A.J., Roth K.A., Macgregor G.R., Thompson C.B., Korsmeyer S.J. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727&#x2013;730. doi: 10.1126/science.1059108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1059108</ArticleId><ArticleId IdType="pmc">PMC3049805</ArticleId><ArticleId IdType="pubmed">11326099</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong W.X., Lindsten T., Ross A.J., MacGregor G.R., Thompson C.B. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 2001;15:1481&#x2013;1486. doi: 10.1101/gad.897601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.897601</ArticleId><ArticleId IdType="pmc">PMC312722</ArticleId><ArticleId IdType="pubmed">11410528</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamorano S., Rojas-Rivera D., Lisbona F., Parra V., Court F.A., Villegas R., Cheng E.H., Korsmeyer S.J., Lavandero S., Hetz C. A BAX/BAK and cyclophilin D-independent intrinsic apoptosis pathway. PLoS ONE. 2012;7:e37782. doi: 10.1371/journal.pone.0037782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0037782</ArticleId><ArticleId IdType="pmc">PMC3373601</ArticleId><ArticleId IdType="pubmed">22719850</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobson M., Jakobson M., Llano O., Palgi J., Arum&#xe4;e U. Multiple mechanisms repress N-Bak mRNA translation in the healthy and apoptotic neurons. Cell Death Dis. 2013;4:e777. doi: 10.1038/cddis.2013.297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.297</ArticleId><ArticleId IdType="pmc">PMC3763458</ArticleId><ArticleId IdType="pubmed">23969856</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Orsi B., Engel T., Pfeiffer S., Nandi S., Kaufmann T., Henshall D.C., Prehn J.H.M. Bok is not pro-apoptotic but suppresses poly ADP-ribose polymerase-dependent cell death pathways and protects against excitotoxic and seizure-induced neuronal injury. J. Neurosci. 2016;36:4564&#x2013;4578. doi: 10.1523/JNEUROSCI.3780-15.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3780-15.2016</ArticleId><ArticleId IdType="pmc">PMC6601822</ArticleId><ArticleId IdType="pubmed">27098698</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Orsi B., Kilbride S.M., Chen G., Alvarez S.P., Bonner H.P., Pfeiffer S., Plesnila N., Engel T., Henshall D.C., D&#xfc;ssmann H., et al. Bax regulates neuronal Ca2+ Homeostasis. J. Neurosci. 2015;35:1706&#x2013;1722. doi: 10.1523/JNEUROSCI.2453-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2453-14.2015</ArticleId><ArticleId IdType="pmc">PMC6795257</ArticleId><ArticleId IdType="pubmed">25632145</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould T.W., Buss R.R., Vinsant S., Prevette D., Sun W., Knudson C.M., Milligan C.E., Oppenheim R.W. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J. Neurosci. 2006;26:8774&#x2013;8786. doi: 10.1523/JNEUROSCI.2315-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2315-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674380</ArticleId><ArticleId IdType="pubmed">16928866</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.I., Deshmukh M. Endoplasmic reticulum stress-induced apoptosis requires bax for commitment and Apaf-1 for execution in primary neurons. Cell Death Differ. 2007;14:1011&#x2013;1019. doi: 10.1038/sj.cdd.4402089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402089</ArticleId><ArticleId IdType="pubmed">17218955</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehranian R., Rose M.E., Vagni V., Pickrell A.M., Griffith R.P., Liu H., Clark R.S.B., Dixon C.E., Kochanek P.M., Graham S.H. Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury. J. Neurotrauma. 2008;25:755&#x2013;767. doi: 10.1089/neu.2007.0441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2007.0441</ArticleId><ArticleId IdType="pmc">PMC2717742</ArticleId><ArticleId IdType="pubmed">18627254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong H.K., Fricker M., Wyttenbach A., Villunger A., Michalak E.M., Strasser A., Tolkovsky A.M. Mutually Exclusive Subsets of BH3-Only Proteins Are Activated by the p53 and c-Jun N-Terminal Kinase/c-Jun Signaling Pathways during Cortical Neuron Apoptosis Induced by Arsenite. Mol. Cell. Biol. 2005;25:8732&#x2013;8747. doi: 10.1128/MCB.25.19.8732-8747.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.25.19.8732-8747.2005</ArticleId><ArticleId IdType="pmc">PMC1265744</ArticleId><ArticleId IdType="pubmed">16166651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyttenbach A., Tolkovsky A.M. The BH3-only protein Puma is both necessary and sufficient for neuronal apoptosis induced by DNA damage in sympathetic neurons. J. Neurochem. 2006;96:1213&#x2013;1226. doi: 10.1111/j.1471-4159.2005.03676.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03676.x</ArticleId><ArticleId IdType="pubmed">16478523</ArticleId></ArticleIdList></Reference><Reference><Citation>Llambi F., Wang Y.M., Victor B., Yang M., Schneider D.M., Gingras S., Parsons M.J., Zheng J.H., Brown S.A., Pelletier S., et al. BOK Is a Non-canonical BCL-2 Family Effector of Apoptosis Regulated by ER-Associated Degradation. Cell. 2016;165:421&#x2013;433. doi: 10.1016/j.cell.2016.02.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.02.026</ArticleId><ArticleId IdType="pmc">PMC5018360</ArticleId><ArticleId IdType="pubmed">26949185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang X., Jiang H., Shen Z., Wang X. Activation of mitochondrial protease OMA1 by bax and bak promotes cytochrome c release during apoptosis. Proc. Natl. Acad. Sci. USA. 2014;111:14782&#x2013;14787. doi: 10.1073/pnas.1417253111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1417253111</ArticleId><ArticleId IdType="pmc">PMC4205663</ArticleId><ArticleId IdType="pubmed">25275009</ArticleId></ArticleIdList></Reference><Reference><Citation>Korwitz A., Merkwirth C., Richter-Dennerlein R., Tr&#xf6;der S.E., Sprenger H.G., Quir&#xf3;s P.M., L&#xf3;pez-Ot&#xed;n C., Rugarli E.I., Langer T. Loss of OMA1 delays neurodegeneration by preventing stress-induced OPA1 processing in mitochondria. J. Cell Biol. 2016;212:157&#x2013;166. doi: 10.1083/jcb.201507022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201507022</ArticleId><ArticleId IdType="pmc">PMC4738383</ArticleId><ArticleId IdType="pubmed">26783299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghavami S., Shojaei S., Yeganeh B., Ande S.R., Jangamreddy J.R., Mehrpour M., Christoffersson J., Chaabane W., Moghadam A.R., Kashani H.H., et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog. Neurobiol. 2014;112:24&#x2013;49. doi: 10.1016/j.pneurobio.2013.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2013.10.004</ArticleId><ArticleId IdType="pubmed">24211851</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichert C.O., de Freitas F.A., Sampaio-Silva J., Rokita-Rosa L., Barros P.d.L., Levy D., Bydlowski S.P. Ferroptosis mechanisms involved in neurodegenerative diseases. Int. J. Mol. Sci. 2020;21:8765. doi: 10.3390/ijms21228765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228765</ArticleId><ArticleId IdType="pmc">PMC7699575</ArticleId><ArticleId IdType="pubmed">33233496</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D., Chen X., Kang R., Kroemer G. Ferroptosis: Molecular mechanisms and health implications. Cell Res. 2021;31:107&#x2013;125. doi: 10.1038/s41422-020-00441-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-00441-1</ArticleId><ArticleId IdType="pmc">PMC8026611</ArticleId><ArticleId IdType="pubmed">33268902</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Hu R., Yu R., Tang Y., Li J. A narrative review of mechanisms of ferroptosis in cancer: New challenges and opportunities. Ann. Transl. Med. 2021;9:1599. doi: 10.21037/atm-21-4863.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/atm-21-4863</ArticleId><ArticleId IdType="pmc">PMC8576726</ArticleId><ArticleId IdType="pubmed">34790805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Lin W., Rao T., Zheng J., Zhang T., Zhang M., Lin Z. Ferroptosis and Its Potential Role in the Nervous System Diseases. J. Inflamm. Res. 2022;15:1555&#x2013;1574. doi: 10.2147/JIR.S351799.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S351799</ArticleId><ArticleId IdType="pmc">PMC8901225</ArticleId><ArticleId IdType="pubmed">35264867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Wang J., Shen Y., Li H., Rausch W.D., Huang X. Iron Dyshomeostasis and Ferroptosis: A New Alzheimer&#x2019;s Disease Hypothesis? Front. Aging Neurosci. 2022;14:235. doi: 10.3389/fnagi.2022.830569.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.830569</ArticleId><ArticleId IdType="pmc">PMC8981915</ArticleId><ArticleId IdType="pubmed">35391749</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y., Wu Z., Xue H., Zhao P. Ferroptosis is involved in regulating perioperative neurocognitive disorders: Emerging perspectives. J. Neuroinflammation. 2022;19:219. doi: 10.1186/s12974-022-02570-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-022-02570-3</ArticleId><ArticleId IdType="pmc">PMC9450301</ArticleId><ArticleId IdType="pubmed">36068571</ArticleId></ArticleIdList></Reference><Reference><Citation>Blesa J., Trigo-Damas I., Quiroga-Varela A., Jackson-Lewis V.R. Oxidative stress and Parkinson&#x2019;s disease. Front. Neuroanat. 2015;9:91. doi: 10.3389/fnana.2015.00091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2015.00091</ArticleId><ArticleId IdType="pmc">PMC4495335</ArticleId><ArticleId IdType="pubmed">26217195</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson W.M., Wilson-Delfosse A.L., Mieyal J.J. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients. 2012;4:1399&#x2013;1440. doi: 10.3390/nu4101399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu4101399</ArticleId><ArticleId IdType="pmc">PMC3497002</ArticleId><ArticleId IdType="pubmed">23201762</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng K., Dong Y., Yang R., Liang Y., Wu H., He Z. Regulation of ferroptosis by bioactive phytochemicals: Implications for medical nutritional therapy. Pharmacol. Res. 2021;168:105580. doi: 10.1016/j.phrs.2021.105580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.105580</ArticleId><ArticleId IdType="pubmed">33781874</ArticleId></ArticleIdList></Reference><Reference><Citation>Corti O., Blomgren K., Poletti A., Beart P.M. Autophagy in neurodegeneration: New insights underpinning therapy for neurological diseases. J. Neurochem. 2020;154:354&#x2013;371. doi: 10.1111/jnc.15002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15002</ArticleId><ArticleId IdType="pubmed">32149395</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanduc D., Mittelman A., Serpico R., Sinigaglia E., Sinha A.A., Natale C., Santacroce R., Di Corcia M.G., Lucchese A., Dini L., et al. Cell death: Apoptosis versus necrosis (review) Int. J. Oncol. 2002;21:165&#x2013;170. doi: 10.3892/ijo.21.1.165.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijo.21.1.165</ArticleId><ArticleId IdType="pubmed">12063564</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 2000;1:120&#x2013;129. doi: 10.1038/35040009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35040009</ArticleId><ArticleId IdType="pubmed">11253364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribe E.M., Serrano-Saiz E., Akpan N., Troy C.M. Mechanisms of neuronal death in disease: Defining the models and the players. Biochem. J. 2008;415:165&#x2013;182. doi: 10.1042/BJ20081118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20081118</ArticleId><ArticleId IdType="pmc">PMC9334905</ArticleId><ArticleId IdType="pubmed">18800967</ArticleId></ArticleIdList></Reference><Reference><Citation>Glushakova O., Glushakov A., Wijesinghe D., Valadka A., Hayes R., Glushakov A. Prospective clinical biomarkers of caspase-mediated apoptosis associated with neuronal and neurovascular damage following stroke and other severe brain injuries: Implications for chronic neurodegeneration. Brain Circ. 2017;3:87. doi: 10.4103/bc.bc_27_16.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/bc.bc_27_16</ArticleId><ArticleId IdType="pmc">PMC6126261</ArticleId><ArticleId IdType="pubmed">30276309</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi F., Cattaneo E. Neural stem cell therapy for neurological diseases: Dreams and reality. Nat. Rev. Neurosci. 2002;3:401&#x2013;409. doi: 10.1038/nrn809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn809</ArticleId><ArticleId IdType="pubmed">11988779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn H.G., Palmer T.D., Fuchs E. Adult neurogenesis: A compensatory mechanism for neuronal damage. Eur. Arch. Psychiatry Clin. Neurosci. 2001;251:152&#x2013;158. doi: 10.1007/s004060170035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004060170035</ArticleId><ArticleId IdType="pubmed">11697579</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpan N., Troy C.M. Caspase inhibitors: Prospective therapies for stroke. Neuroscientist. 2013;19:129&#x2013;136. doi: 10.1177/1073858412447875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858412447875</ArticleId><ArticleId IdType="pmc">PMC9214550</ArticleId><ArticleId IdType="pubmed">22645109</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amelio M., Cavallucci V., Cecconi F. Neuronal caspase-3 signaling: Not only cell death. Cell Death Differ. 2010;17:1104&#x2013;1114. doi: 10.1038/cdd.2009.180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2009.180</ArticleId><ArticleId IdType="pubmed">19960023</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy C.M., Akpan N., Jean Y.Y. Regulation of caspases in the nervous system: Implications for functions in health and disease. Prog. Mol. Biol. Transl. Sci. 2011;99:265&#x2013;305. doi: 10.1016/B978-0-12-385504-6.00007-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-385504-6.00007-5</ArticleId><ArticleId IdType="pmc">PMC9214546</ArticleId><ArticleId IdType="pubmed">21238939</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth K.A., D&#x2019;Sa C. Apoptosis and brain development. Ment. Retard. Dev. Disabil. Res. Rev. 2001;7:261&#x2013;266. doi: 10.1002/mrdd.1036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrdd.1036</ArticleId><ArticleId IdType="pubmed">11754520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferriero D.M., Miller S.P. Imaging selective vulnerability in the developing nervous system. J. Anat. 2010;217:429&#x2013;435. doi: 10.1111/j.1469-7580.2010.01226.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-7580.2010.01226.x</ArticleId><ArticleId IdType="pmc">PMC2992418</ArticleId><ArticleId IdType="pubmed">20408904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaidi A.U., D&#x2019;Sa-Eipper C., Brenner J., Kuida K., Zheng T.S., Flavell R.A., Rakic P., Roth K.A. Bcl-XL-caspase-9 interactions in the developing nervous system: Evidence for multiple death pathways. J. Neurosci. 2001;21:169&#x2013;175. doi: 10.1523/JNEUROSCI.21-01-00169.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-01-00169.2001</ArticleId><ArticleId IdType="pmc">PMC6762421</ArticleId><ArticleId IdType="pubmed">11150333</ArticleId></ArticleIdList></Reference><Reference><Citation>Idda M.L., Munk R., Abdelmohsen K., Gorospe M. Noncoding RNAs in Alzheimer&#x2019;s disease. WIREs RNA. 2018;9:e1463. doi: 10.1002/wrna.1463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/wrna.1463</ArticleId><ArticleId IdType="pmc">PMC5847280</ArticleId><ArticleId IdType="pubmed">29327503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao S., Fisher D.W., Yu T., Dong H. The link between chronic pain and Alzheimer&#x2019;s disease. J. Neuroinflammation. 2019;16:204. doi: 10.1186/s12974-019-1608-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1608-z</ArticleId><ArticleId IdType="pmc">PMC6836339</ArticleId><ArticleId IdType="pubmed">31694670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires G., McElligott S., Drusinsky S., Halliday G., Potier M.C., Wisniewski T., Drummond E. Secernin-1 is a novel phosphorylated tau binding protein that accumulates in Alzheimer&#x2019;s disease and not in other tauopathies. Acta Neuropathol. Commun. 2019;7:195. doi: 10.1186/s40478-019-0848-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0848-6</ArticleId><ArticleId IdType="pmc">PMC6892024</ArticleId><ArticleId IdType="pubmed">31796108</ArticleId></ArticleIdList></Reference><Reference><Citation>He Z., Guo J.L., McBride J.D., Narasimhan S., Kim H., Changolkar L., Zhang B., Gathagan R.J., Yue C., Dengler C., et al. Amyloid-&#x3b2; plaques enhance Alzheimer&#x2019;s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med. 2018;24:29&#x2013;38. doi: 10.1038/nm.4443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4443</ArticleId><ArticleId IdType="pmc">PMC5760353</ArticleId><ArticleId IdType="pubmed">29200205</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan A., Das S., Sergi C. Therapeutic Potential of Neu1 in Alzheimer&#x2019;s Disease Via the Immune System. Am. J. Alzheimers Dis. Other Demen. 2021;36:153331752199614. doi: 10.1177/1533317521996147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1533317521996147</ArticleId><ArticleId IdType="pubmed">33719595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas G., Acu&#xf1;a-Hidalgo R., Keogh M.J., Quenez O., Steehouwer M., Lelieveld S., Rousseau S., Richard A.C., Oud M.S., Marguet F., et al. Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2018;14:1632&#x2013;1639. doi: 10.1016/j.jalz.2018.06.3056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2018.06.3056</ArticleId><ArticleId IdType="pmc">PMC6544509</ArticleId><ArticleId IdType="pubmed">30114415</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha A.L., Costa A., Garrett M.C., Meireles J. Difficult case of a rare form of familial Alzheimer&#x2019;s disease with PSEN1 P117L mutation. BMJ Case Rep. 2018;11:e226664. doi: 10.1136/bcr-2018-226664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2018-226664</ArticleId><ArticleId IdType="pmc">PMC6301458</ArticleId><ArticleId IdType="pubmed">30567237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiedt H.O., Benjamin B., Niedeggen M., Lueschow A. Phenotypic Variability in Autosomal Dominant Familial Alzheimer Disease due to the S170F Mutation of Presenilin-1. Neurodegener. Dis. 2018;18:57&#x2013;68. doi: 10.1159/000485899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000485899</ArticleId><ArticleId IdType="pubmed">29466804</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C.Y., Sun L., Chen X.P., Zhang D.S. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen. Res. 2013;8:2003&#x2013;2014. doi: 10.3969/j.issn.1673-5374.2013.21.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.3969/j.issn.1673-5374.2013.21.009</ArticleId><ArticleId IdType="pmc">PMC4145906</ArticleId><ArticleId IdType="pubmed">25206509</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Long M., Qin Z., Wang F., Chen Z., Li L. Nicorandil inhibits cardiomyocyte apoptosis and improves cardiac function by suppressing the HtrA2/XIAP/PARP signaling after coronary microembolization in rats. Pharmacol. Res. Perspect. 2021;9:e00699. doi: 10.1002/prp2.699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.699</ArticleId><ArticleId IdType="pmc">PMC7809785</ArticleId><ArticleId IdType="pubmed">33448699</ArticleId></ArticleIdList></Reference><Reference><Citation>Obulesu M., Lakshmi M.J. Apoptosis in Alzheimer&#x2019;s Disease: An Understanding of the Physiology, Pathology and Therapeutic Avenues. Neurochem. Res. 2014;39:2301&#x2013;2312. doi: 10.1007/s11064-014-1454-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-014-1454-4</ArticleId><ArticleId IdType="pubmed">25322820</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.G., Kwon H.Y., Sohn E.J., Hwang S., Kwon O.S., Kim S.-H. Activation of caspases and inhibition of ribosome biogenesis mediate antitumor activity of Chijongdan in A549 non-small lung cancer cells. BMC Complement. Altern. Med. 2014;14:420. doi: 10.1186/1472-6882-14-420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-14-420</ArticleId><ArticleId IdType="pmc">PMC4226917</ArticleId><ArticleId IdType="pubmed">25345917</ArticleId></ArticleIdList></Reference><Reference><Citation>Park G., Nhan H.S., Tyan S.H., Kawakatsu Y., Zhang C., Navarro M., Koo E.H. Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid &#x3b2;-Protein-Induced Synapse Loss in Alzheimer&#x2019;s Disease. Cell Rep. 2020;31:107839. doi: 10.1016/j.celrep.2020.107839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.107839</ArticleId><ArticleId IdType="pmc">PMC7375398</ArticleId><ArticleId IdType="pubmed">32610140</ArticleId></ArticleIdList></Reference><Reference><Citation>Roher A.E., Kokjohn T.A., Clarke S.G., Sierks M.R., Maarouf C.L., Serrano G.E., Sabbagh M.S., Beach T.G. APP/A&#x3b2; structural diversity and Alzheimer&#x2019;s disease pathogenesis. Neurochem. Int. 2017;110:1&#x2013;13. doi: 10.1016/j.neuint.2017.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2017.08.007</ArticleId><ArticleId IdType="pmc">PMC5688956</ArticleId><ArticleId IdType="pubmed">28811267</ArticleId></ArticleIdList></Reference><Reference><Citation>Turunc Bayrakdar E., Uyanikgil Y., Kanit L., Koylu E., Yalcin A. Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in A&#x3b2;(1-42)-induced rat model of Alzheimer&#x2019;s disease. Free Radic. Res. 2014;48:146&#x2013;158. doi: 10.3109/10715762.2013.857018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10715762.2013.857018</ArticleId><ArticleId IdType="pubmed">24151909</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q.S., Liu W., Lu G.X. miR-200a-3p promotes &#x3b2;-Amyloid-induced neuronal apoptosis through down-regulation of SIRT1 in Alzheimer&#x2019;s disease. J. Biosci. 2017;42:397&#x2013;404. doi: 10.1007/s12038-017-9698-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12038-017-9698-1</ArticleId><ArticleId IdType="pubmed">29358553</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheignon C., Tomas M., Bonnefont-Rousselot D., Faller P., Hureau C., Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer&#x2019;s disease. Redox Biol. 2018;14:450&#x2013;464. doi: 10.1016/j.redox.2017.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.014</ArticleId><ArticleId IdType="pmc">PMC5680523</ArticleId><ArticleId IdType="pubmed">29080524</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G.F., Xu T.H., Yan Y., Zhou Y.R., Jiang Y., Melcher K., Xu H.E. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 2017;38:1205&#x2013;1235. doi: 10.1038/aps.2017.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2017.28</ArticleId><ArticleId IdType="pmc">PMC5589967</ArticleId><ArticleId IdType="pubmed">28713158</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia-Rojas C., Cabezas-Opazo F., Deaton C.A., Vergara E.H., Johnson G.V.W., Quintanilla R.A. It&#x2019;s all about tau. Prog. Neurobiol. 2019;175:54&#x2013;76. doi: 10.1016/j.pneurobio.2018.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2018.12.005</ArticleId><ArticleId IdType="pmc">PMC6397676</ArticleId><ArticleId IdType="pubmed">30605723</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurcau A. The role of natural antioxidants in the prevention of dementia&#x2014;Where do we stand and future perspectives. Nutrients. 2021;13:282. doi: 10.3390/nu13020282.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13020282</ArticleId><ArticleId IdType="pmc">PMC7909256</ArticleId><ArticleId IdType="pubmed">33498262</ArticleId></ArticleIdList></Reference><Reference><Citation>Honarnejad K., Jung C.K.E., Lammich S., Arzberger T., Kretzschmar H., Herms J. Involvement of presenilin holoprotein upregulation in calcium dyshomeostasis of Alzheimer&#x2019;s disease. J. Cell. Mol. Med. 2013;17:293&#x2013;302. doi: 10.1111/jcmm.12008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.12008</ArticleId><ArticleId IdType="pmc">PMC3822592</ArticleId><ArticleId IdType="pubmed">23379308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng L., Hu C., Zhang F., Xu D.C., Cui M.Z., Xu X. Cellular FLICE-like inhibitory protein (c-FLIP) and PS1-associated protein (PSAP) mediate presenilin 1-induced &#x3b3;-secretase-dependent and -independent apoptosis, respectively. J. Biol. Chem. 2015;290:18269&#x2013;18280. doi: 10.1074/jbc.M115.640177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.640177</ArticleId><ArticleId IdType="pmc">PMC4513088</ArticleId><ArticleId IdType="pubmed">26025363</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocernich C.B., Butterfield D.A. Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim. Biophys. Acta Mol. Basis Dis. 2012;1822:625&#x2013;630. doi: 10.1016/j.bbadis.2011.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.10.003</ArticleId><ArticleId IdType="pmc">PMC3277671</ArticleId><ArticleId IdType="pubmed">22015471</ArticleId></ArticleIdList></Reference><Reference><Citation>Braidy N., Zarka M., Welch J., Bridge W. Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer&#x2019;s Disease. Curr. Alzheimer Res. 2015;12:298&#x2013;313. doi: 10.2174/1567205012666150302160308.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205012666150302160308</ArticleId><ArticleId IdType="pubmed">25731620</ArticleId></ArticleIdList></Reference><Reference><Citation>Neddens J., Temmel M., Flunkert S., Kerschbaumer B., Hoeller C., Loeffler T., Niederkofler V., Daum G., Attems J., Hutter-Paier B. Phosphorylation of different tau sites during progression of Alzheimer&#x2019;s disease. Acta Neuropathol. Commun. 2018;6:52. doi: 10.1186/s40478-018-0557-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0557-6</ArticleId><ArticleId IdType="pmc">PMC6027763</ArticleId><ArticleId IdType="pubmed">29958544</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K.A. Interaction between pathogenic proteins in neurodegenerative disorders. J. Cell. Mol. Med. 2012;16:1166&#x2013;1183. doi: 10.1111/j.1582-4934.2011.01507.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2011.01507.x</ArticleId><ArticleId IdType="pmc">PMC3823071</ArticleId><ArticleId IdType="pubmed">22176890</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Pu J. Alpha-Synuclein in Parkinson&#x2019;s Disease: From Pathogenetic Dysfunction to Potential Clinical Application. Parkinsons Dis. 2016;2016:1720621. doi: 10.1155/2016/1720621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/1720621</ArticleId><ArticleId IdType="pmc">PMC5005546</ArticleId><ArticleId IdType="pubmed">27610264</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Benito M., Granado N., Garc&#xed;a-Sanz P., Michel A., Dumoulin M., Moratalla R. Modeling Parkinson&#x2019;s Disease with the Alpha-Synuclein Protein. Front. Pharmacol. 2020;11:356. doi: 10.3389/fphar.2020.00356.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00356</ArticleId><ArticleId IdType="pmc">PMC7191035</ArticleId><ArticleId IdType="pubmed">32390826</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen J.S., Smith M.M., Long J.D. Cognitive decline in prodromal Huntington disease: Implications for clinical trials. J. Neurol. Neurosurg. Psychiatry. 2013;84:1233&#x2013;1239. doi: 10.1136/jnnp-2013-305114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-305114</ArticleId><ArticleId IdType="pmc">PMC3795884</ArticleId><ArticleId IdType="pubmed">23911948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed Z., Asi Y.T., Sailer A., Lees A.J., Houlden H., Revesz T., Holton J.L. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol. 2012;38:4&#x2013;24. doi: 10.1111/j.1365-2990.2011.01234.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.2011.01234.x</ArticleId><ArticleId IdType="pubmed">22074330</ArticleId></ArticleIdList></Reference><Reference><Citation>Saberi S., Stauffer J.E., Schulte D.J., Ravits J. Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol. Clin. 2015;33:855&#x2013;876. doi: 10.1016/j.ncl.2015.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.012</ArticleId><ArticleId IdType="pmc">PMC4628785</ArticleId><ArticleId IdType="pubmed">26515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera L.C., Leigh P.N. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Youssef K., Tandon A., Rezai P. Studying Parkinson&#x2019;s disease using Caenorhabditis elegans models in microfluidic devices. Integr. Biol. 2019;11:186&#x2013;207. doi: 10.1093/intbio/zyz017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intbio/zyz017</ArticleId><ArticleId IdType="pubmed">31251339</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia Guedes L., Mestre T., Outeiro T.F., Ferreira J.J. Are genetic and idiopathic forms of Parkinson&#x2019;s disease the same disease? J. Neurochem. 2020;152:515&#x2013;522. doi: 10.1111/jnc.14902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14902</ArticleId><ArticleId IdType="pubmed">31643079</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoker T.B., Torsney K.M., Barker R.A. Emerging Treatment Approaches for Parkinson&#x2019;s Disease. Front. Neurosci. 2018;12:45&#x2013;64. doi: 10.3389/fnins.2018.00693.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2018.00693</ArticleId><ArticleId IdType="pmc">PMC6186796</ArticleId><ArticleId IdType="pubmed">30349448</ArticleId></ArticleIdList></Reference><Reference><Citation>Balestrino R., Schapira A.H.V. Parkinson disease. Eur. J. Neurol. 2020;27:27&#x2013;42. doi: 10.1111/ene.14108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14108</ArticleId><ArticleId IdType="pubmed">31631455</ArticleId></ArticleIdList></Reference><Reference><Citation>Borsche M., Pereira S.L., Klein C., Gr&#xfc;newald A. Mitochondria and Parkinson&#x2019;s disease: Clinical, molecular, and translational aspects. J. Parkinsons Dis. 2021;11:45&#x2013;60. doi: 10.3233/JPD-201981.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-201981</ArticleId><ArticleId IdType="pmc">PMC7990451</ArticleId><ArticleId IdType="pubmed">33074190</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen S.B., Hanss Z., Kr&#xfc;ger R. The genetic architecture of mitochondrial dysfunction in Parkinson&#x2019;s disease. Cell Tissue Res. 2018;373:21&#x2013;37. doi: 10.1007/s00441-017-2768-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-017-2768-8</ArticleId><ArticleId IdType="pmc">PMC6015629</ArticleId><ArticleId IdType="pubmed">29372317</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrentino Z.A., Giasson B.I. The emerging role of &#x3b1;-synuclein truncation in aggregation and disease. J. Biol. Chem. 2020;295:10224&#x2013;10244. doi: 10.1074/jbc.REV120.011743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.REV120.011743</ArticleId><ArticleId IdType="pmc">PMC7383394</ArticleId><ArticleId IdType="pubmed">32424039</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J., Sharma M., S&#xfc;dhof T.C. Cell biology and pathophysiology of &#x3b1;-synuclein. Cold Spring Harb. Perspect. Med. 2018;8:a024091. doi: 10.1101/cshperspect.a024091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a024091</ArticleId><ArticleId IdType="pmc">PMC5519445</ArticleId><ArticleId IdType="pubmed">28108534</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeve A.K., Ludtmann M.H.R., Angelova P.R., Simcox E.M., Horrocks M.H., Klenerman D., Gandhi S., Turnbull D.M., Abramov A.Y. Aggregated &#x3b1;-synuclein and complex I deficiency: Exploration of their relationship in differentiated neurons. Cell Death Dis. 2015;6:e1820. doi: 10.1038/cddis.2015.166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2015.166</ArticleId><ArticleId IdType="pmc">PMC4650719</ArticleId><ArticleId IdType="pubmed">26181201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocha E.M., De Miranda B., Sanders L.H. Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson&#x2019;s disease. Neurobiol. Dis. 2018;109:249&#x2013;257. doi: 10.1016/j.nbd.2017.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.04.004</ArticleId><ArticleId IdType="pubmed">28400134</ArticleId></ArticleIdList></Reference><Reference><Citation>Salehi M., Nikkhah M., Mohammadi S., Hosseinkhani S. Transient transfection of WT-&#x3b1;S and A53T-&#x3b1;S brought about a mild apoptosis due to degradation of released cytochrome c through PARC. Int. J. Biol. Macromol. 2021;166:374&#x2013;384. doi: 10.1016/j.ijbiomac.2020.10.196.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2020.10.196</ArticleId><ArticleId IdType="pubmed">33122072</ArticleId></ArticleIdList></Reference><Reference><Citation>Bose A., Beal M.F. Mitochondrial dysfunction in Parkinson&#x2019;s disease. J. Neurochem. 2016;139:216&#x2013;231. doi: 10.1111/jnc.13731.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13731</ArticleId><ArticleId IdType="pubmed">27546335</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad D., Nakamura K. Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson&#x2019;s disease. FEBS Lett. 2015;589:3702&#x2013;3713. doi: 10.1016/j.febslet.2015.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2015.10.021</ArticleId><ArticleId IdType="pmc">PMC4679488</ArticleId><ArticleId IdType="pubmed">26526613</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q., Zhu X., Xu M. Silencing of TRIM10 alleviates apoptosis in cellular model of Parkinson&#x2019;s disease. Biochem. Biophys. Res. Commun. 2019;518:451&#x2013;458. doi: 10.1016/j.bbrc.2019.08.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.08.041</ArticleId><ArticleId IdType="pubmed">31472958</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X.L., Wang Y.D., Yu X.M., Li D.W., Li G.R. Mitochondria-mediated damage to dopaminergic neurons in Parkinson&#x2019;s disease (Review) Int. J. Mol. Med. 2018;41:615&#x2013;623. doi: 10.3892/ijmm.2017.3255.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2017.3255</ArticleId><ArticleId IdType="pubmed">29207041</ArticleId></ArticleIdList></Reference><Reference><Citation>Vauzour D., Pinto J.T., Cooper A.J.L., Spencer J.P.E. The neurotoxicity of 5-S-cysteinyldopamine is mediated by the early activation of ERK1/2 followed by the subsequent activation of ASK1/JNK1/2 pro-apoptotic signaling. Biochem. J. 2014;463:41&#x2013;52. doi: 10.1042/BJ20131519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20131519</ArticleId><ArticleId IdType="pubmed">24938188</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan S., Tian L., Fang R. Chlorogenic acid exerts beneficial effects in 6-hydroxydopamine-induced neurotoxicity by inhibition of endoplasmic reticulum stress. Med. Sci. Monit. 2019;25:453&#x2013;459. doi: 10.12659/MSM.911166.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.911166</ArticleId><ArticleId IdType="pmc">PMC6342059</ArticleId><ArticleId IdType="pubmed">30645211</ArticleId></ArticleIdList></Reference><Reference><Citation>Venderova K., Park D.S. Programmed cell death in Parkinson&#x2019;s disease. Cold Spring Harb. Perspect. Med. 2012;2:a009365. doi: 10.1101/cshperspect.a009365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a009365</ArticleId><ArticleId IdType="pmc">PMC3405826</ArticleId><ArticleId IdType="pubmed">22908196</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-R., Chang H.-C., Cheng Y.-D., Lan W.-C., Yang S.-E., Ching H. Aqueous Extract of Davallia mariesii Attenuates 6-Hydroxydopamine-Induced Oxidative Damage and Apoptosis in B35 Cells Through Inhibition of Caspase Cascade and Activation of PI3K/AKT/GSK-3&#x3b2; Pathway. Nutrients. 2018;10:1449. doi: 10.3390/nu10101449.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu10101449</ArticleId><ArticleId IdType="pmc">PMC6213869</ArticleId><ArticleId IdType="pubmed">30301204</ArticleId></ArticleIdList></Reference><Reference><Citation>Konnova E.A., Swanberg M. Parkinson&#x2019;s Disease: Pathogenesis and Clinical Aspects. Codon Publications; Singapore: 2018. Animal Models of Parkinson&#x2019;s Disease; pp. 83&#x2013;106.</Citation></Reference><Reference><Citation>Su J., Zhang J., Bao R., Xia C., Zhang Y., Zhu Z., Lv Q., Qi Y., Xue J. Mitochondrial dysfunction and apoptosis are attenuated through activation of AMPK/GSK-3&#x3b2;/PP2A pathway in Parkinson&#x2019;s disease. Eur. J. Pharmacol. 2021;907:174202. doi: 10.1016/j.ejphar.2021.174202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174202</ArticleId><ArticleId IdType="pubmed">34048739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickey A.S., La Spada A.R. Therapy development in Huntington disease: From current strategies to emerging opportunities. Am. J. Med. Genet. Part A. 2018;176:842&#x2013;861. doi: 10.1002/ajmg.a.38494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.a.38494</ArticleId><ArticleId IdType="pmc">PMC5975251</ArticleId><ArticleId IdType="pubmed">29218782</ArticleId></ArticleIdList></Reference><Reference><Citation>Testa C.M., Jankovic J. Huntington disease: A quarter century of progress since the gene discovery. J. Neurol. Sci. 2019;396:52&#x2013;68. doi: 10.1016/j.jns.2018.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2018.09.022</ArticleId><ArticleId IdType="pubmed">30419368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogomazova A.N., Eremeev A.V., Pozmogova G.E., Lagarkova M.A. The Role of Mutant RNA in the Pathogenesis of Huntington&#x2019;s Disease and Other Polyglutamine Diseases. Mol. Biol. 2019;53:838&#x2013;849. doi: 10.1134/S0026893319060037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0026893319060037</ArticleId><ArticleId IdType="pubmed">31876275</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekman F.K., Ojala D.S., Adil M.M., Lopez P.A., Schaffer D.V., Gaj T. CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington&#x2019;s Disease Mouse Model. Mol. Ther. Nucleic Acids. 2019;17:829&#x2013;839. doi: 10.1016/j.omtn.2019.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.07.009</ArticleId><ArticleId IdType="pmc">PMC6717077</ArticleId><ArticleId IdType="pubmed">31465962</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh R., Wood-Kaczmar A., Dobson L., Smith E.J., Sirinathsinghji E.C., Kriston-Vizi J., Hargreaves I.P., Heaton R., Herrmann F., Abramov A.Y., et al. Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction. FASEB J. 2020;34:8139&#x2013;8154. doi: 10.1096/fj.201902277RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201902277RR</ArticleId><ArticleId IdType="pmc">PMC8432155</ArticleId><ArticleId IdType="pubmed">32329133</ArticleId></ArticleIdList></Reference><Reference><Citation>McColgan P., Tabrizi S.J. Huntington&#x2019;s disease: A clinical review. Eur. J. Neurol. 2018;25:24&#x2013;34. doi: 10.1111/ene.13413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13413</ArticleId><ArticleId IdType="pubmed">28817209</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantiya P., Thonusin C., Chattipakorn N., Chattipakorn S.C. Mitochondrial abnormalities in neurodegenerative models and possible interventions: Focus on Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, Huntington&#x2019;s disease. Mitochondrion. 2020;55:14&#x2013;47. doi: 10.1016/j.mito.2020.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2020.08.003</ArticleId><ArticleId IdType="pubmed">32828969</ArticleId></ArticleIdList></Reference><Reference><Citation>McAdam R.L., Morton A., Gordon S.L., Alterman J.F., Khvorova A., Cousin M.A., Smillie K.J. Loss of huntingtin function slows synaptic vesicle endocytosis in striatal neurons from the httQ140/Q140 mouse model of Huntington&#x2019;s disease. Neurobiol. Dis. 2020;134:104637. doi: 10.1016/j.nbd.2019.104637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104637</ArticleId><ArticleId IdType="pubmed">31614197</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuing L., Chiu C.T., Liao H.M., Linares G.R., Chuang D.M. Preclinical and clinical investigations of mood stabilizers for Huntington&#x2019;s disease: What have we learned? Int. J. Biol. Sci. 2014;10:1021&#x2013;1038. doi: 10.7150/ijbs.9898.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.9898</ArticleId><ArticleId IdType="pmc">PMC4183923</ArticleId><ArticleId IdType="pubmed">25285035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickey M.A., Chesselet M.F. Apoptosis in Huntington&#x2019;s disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2003;27:255&#x2013;265. doi: 10.1016/S0278-5846(03)00021-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0278-5846(03)00021-6</ArticleId><ArticleId IdType="pubmed">12657365</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya N.P., Banerjee M., Majumder P. Huntington&#x2019;s disease: Roles of huntingtin-interacting protein 1 (HIP-1) and its molecular partner HIPPI in the regulation of apoptosis and transcription. FEBS J. 2008;275:4271&#x2013;4279. doi: 10.1111/j.1742-4658.2008.06563.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-4658.2008.06563.x</ArticleId><ArticleId IdType="pubmed">18637945</ArticleId></ArticleIdList></Reference><Reference><Citation>Jodeiri Farshbaf M., Ghaedi K. Huntington&#x2019;s Disease and Mitochondria. Neurotox. Res. 2017;32:518&#x2013;529. doi: 10.1007/s12640-017-9766-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-017-9766-1</ArticleId><ArticleId IdType="pubmed">28639241</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldvogel H.J., Kim E.H., Thu D.C.V., Tippett L.J., Faull R.L.M. New perspectives on the neuropathology in Huntington&#x2019;s disease in the human brain and its relation to symptom variation. J. Huntingtons. Dis. 2012;1:143&#x2013;153. doi: 10.3233/JHD-2012-120018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-2012-120018</ArticleId><ArticleId IdType="pubmed">25063328</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L., Chew Y.L., Lum J.S., Geraghty N.J., Yerbury J.J., Cashman N.R. Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises. Front. Cell. Neurosci. 2020;14:581907. doi: 10.3389/fncel.2020.581907.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.581907</ArticleId><ArticleId IdType="pmc">PMC7671971</ArticleId><ArticleId IdType="pubmed">33328890</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarei S., Carr K., Reiley L., Diaz K., Guerra O., Altamirano P.F., Pagani W., Lodin D., Orozco G., Chinea A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 2015;6:171. doi: 10.4103/2152-7806.169561.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2152-7806.169561</ArticleId><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Guissart C., Mouzat K., Kantar J., Louveau B., Vilquin P., Polge A., Raoul C., Lumbroso S. Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay. Sci. Rep. 2020;10:1&#x2013;7. doi: 10.1038/s41598-020-77716-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-77716-5</ArticleId><ArticleId IdType="pmc">PMC7691510</ArticleId><ArticleId IdType="pubmed">33244158</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa A.C., Corsi D., Cavi N., Bruni N., Dosio F. Superoxide dismutase administration: A review of proposed human uses. Molecules. 2021;26:1844. doi: 10.3390/molecules26071844.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26071844</ArticleId><ArticleId IdType="pmc">PMC8037464</ArticleId><ArticleId IdType="pubmed">33805942</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith E.F., Shaw P.J., De Vos K.J. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;710:132933. doi: 10.1016/j.neulet.2017.06.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.06.052</ArticleId><ArticleId IdType="pubmed">28669745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sathasivam S., Shaw P.J. Apoptosis in amyotrophic lateral sclerosis&#x2014;What is the evidence? Lancet Neurol. 2005;4:500&#x2013;509. doi: 10.1016/S1474-4422(05)70142-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70142-3</ArticleId><ArticleId IdType="pubmed">16033692</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xf1;i-Oliver P., Lucas J.J., Avila J., Hern&#xe1;ndez F. N-terminal cleavage of GSK-3 by calpain: A new form of GSK-3 regulation. J. Biol. Chem. 2007;282:22406&#x2013;22413. doi: 10.1074/jbc.M702793200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M702793200</ArticleId><ArticleId IdType="pubmed">17569662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez F., Nido J., Avila J., Villanueva N. GSK3 Inhibitors and Disease. Mini-Rev. Med. Chem. 2009;9:1024&#x2013;1029. doi: 10.2174/138955709788922647.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138955709788922647</ArticleId><ArticleId IdType="pubmed">19689399</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez A., Perez D.I. GSK-3 inhibitors: A ray of hope for the treatment of Alzheimer&#x2019;s disease? J. Alzheimer&#x2019;s Dis. 2008;15:181&#x2013;191. doi: 10.3233/JAD-2008-15204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-15204</ArticleId><ArticleId IdType="pubmed">18953107</ArticleId></ArticleIdList></Reference><Reference><Citation>Selenica M.L., Jensen H.S., Larsen A.K., Pedersen M.L., Helboe L., Leist M., Lotharius J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 2007;152:959&#x2013;979. doi: 10.1038/sj.bjp.0707471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.bjp.0707471</ArticleId><ArticleId IdType="pmc">PMC2078230</ArticleId><ArticleId IdType="pubmed">17906685</ArticleId></ArticleIdList></Reference><Reference><Citation>Camins A., Verdaguer E., Junyent F., Yeste-Velasco M., Pelegr&#xed; C., Vilaplana J., Pall&#xe1;s M. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci. Ther. 2009;15:333&#x2013;344. doi: 10.1111/j.1755-5949.2009.00086.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00086.x</ArticleId><ArticleId IdType="pmc">PMC6494035</ArticleId><ArticleId IdType="pubmed">19889130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: A drug target for CNS therapies. J. Neurochem. 2004;89:1313&#x2013;1317. doi: 10.1111/j.1471-4159.2004.02422.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02422.x</ArticleId><ArticleId IdType="pubmed">15189333</ArticleId></ArticleIdList></Reference><Reference><Citation>Crespo-Biel N., Camins A., Guti&#xe9;rrez-Cuesta J., Melchiorri D., Nicoletti F., Pall&#xe0;s M., Canudas A.M. Regulation of GSK-3&#x3b2; by calpain in the 3-nitropropionic acid model. Hippocampus. 2009;20:962&#x2013;970. doi: 10.1002/hipo.20691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20691</ArticleId><ArticleId IdType="pubmed">19714564</ArticleId></ArticleIdList></Reference><Reference><Citation>Leyhe T., Eschweiler G.W., Stransky E., Gasser T., Annas P., Basun H., Laske C. Increase of bdnf serum concentration in lithium treated patients with early alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. 2009;16:649&#x2013;656. doi: 10.3233/JAD-2009-1004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1004</ArticleId><ArticleId IdType="pubmed">19276559</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes P.V., Forlenza O.V., Gattaz W.F. Lithium and risk for Alzheimer&#x2019;s disease in elderly patients with bipolar disorder. Br. J. Psychiatry. 2007;190:359&#x2013;360. doi: 10.1192/bjp.bp.106.029868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/bjp.bp.106.029868</ArticleId><ArticleId IdType="pubmed">17401045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S., Stavrovskaya I.G., Drozda M., Kim B.Y.S., Ona V., Li M., Sarang S., Liu A.S., Hartley D.M., Wu D.C., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74&#x2013;78. doi: 10.1038/417074a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/417074a</ArticleId><ArticleId IdType="pubmed">11986668</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Sugama S., Chirichigno J.W., Gregorio J., Lorenzl S., Shin D.H., Browne S.E., Shimizu Y., Joh T.H., Beal M.F., et al. Minocycline enhances MPTP toxicity to dopaminergic neurons. J. Neurosci. Res. 2003;74:278&#x2013;285. doi: 10.1002/jnr.10709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10709</ArticleId><ArticleId IdType="pubmed">14515357</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas M., Le W.D., Jankovic J. Minocycline and Other Tetracycline Derivatives: A Neuroprotective Strategy in Parkinson&#x2019;s Disease and Huntington&#x2019;s Disease. Clin. Neuropharmacol. 2003;26:18&#x2013;23. doi: 10.1097/00002826-200301000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002826-200301000-00005</ArticleId><ArticleId IdType="pubmed">12567160</ArticleId></ArticleIdList></Reference><Reference><Citation>Intihar T.A., Martinez E.A., Gomez-Pastor R. Mitochondrial dysfunction in huntington&#x2019;s disease; interplay between HSF1, p53 and PGC-1&#x3b1; transcription factors. Front. Cell. Neurosci. 2019;13:103. doi: 10.3389/fncel.2019.00103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00103</ArticleId><ArticleId IdType="pmc">PMC6433789</ArticleId><ArticleId IdType="pubmed">30941017</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Fu X., Chen X., Chen X., Zhao Y. Mitochondrial Uncoupling Inhibits p53 Mitochondrial Translocation in TPA-Challenged Skin Epidermal JB6 Cells. PLoS ONE. 2010;5:e13459. doi: 10.1371/journal.pone.0013459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0013459</ArticleId><ArticleId IdType="pmc">PMC2956637</ArticleId><ArticleId IdType="pubmed">20976134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatton W.G., Chalmers-Redman R., Brown D., Tatton N. Apoptosis in Parkinson&#x2019;s disease: Signals for neuronal degradation. Ann. Neurol. 2003;53:S61&#x2013;S72. doi: 10.1002/ana.10489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10489</ArticleId><ArticleId IdType="pubmed">12666099</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulliam L., Irwin I., Kusdra L., Rempel H., Flitter W.D., Garland W.A. CPI-1189 attenuates effects of suspected neurotoxins associated with AIDS dementia: A possible role for ERK activation. Brain Res. 2001;893:95&#x2013;103. doi: 10.1016/S0006-8993(00)03293-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(00)03293-5</ArticleId><ArticleId IdType="pubmed">11222997</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatton W., Chalmers-Redman R., Tatton N. Neuroprotection by deprenyl and other propargylamines: Glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J. Neural Transm. 2003;110:509&#x2013;515. doi: 10.1007/s00702-002-0827-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-002-0827-z</ArticleId><ArticleId IdType="pubmed">12721812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatton W.G., Chalmers-Redman R.M.E., Ju W.J.H., Mammen M., Carlile G.W., Pong A.W., Tatton N.A. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 2002;301:753&#x2013;764. doi: 10.1124/jpet.301.2.753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.301.2.753</ArticleId><ArticleId IdType="pubmed">11961082</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlile G.W., Chalmers-Redman R.M.E., Tatton N.A., Pong A., Borden K.L.B., Tatton W.G. Reduced Apoptosis after Nerve Growth Factor and Serum Withdrawal: Conversion of Tetrameric Glyceraldehyde-3-Phosphate Dehydrogenase to a Dimer. Mol. Pharmacol. 2000;57:2&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">10617673</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmeier P.C. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2003;27:303&#x2013;321. doi: 10.1016/S0278-5846(03)00025-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0278-5846(03)00025-3</ArticleId><ArticleId IdType="pubmed">12657369</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L.H., Besirli C.G., Johnson E.M. Mixed-Lineage Kinases: A Target for the Prevention of Neurodegeneration. Annu. Rev. Pharmacol. Toxicol. 2004;44:451&#x2013;474. doi: 10.1146/annurev.pharmtox.44.101802.121840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.44.101802.121840</ArticleId><ArticleId IdType="pubmed">14744254</ArticleId></ArticleIdList></Reference><Reference><Citation>Weishaupt J.H., Bartels C., P&#xf6;lking E., Dietrich J., Rohde G., Poeggeler B., Mertens N., Sperling S., Bohn M., H&#xfc;ther G., et al. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J. Pineal Res. 2006;41:313&#x2013;323. doi: 10.1111/j.1600-079X.2006.00377.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2006.00377.x</ArticleId><ArticleId IdType="pubmed">17014688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesudason E.P., Baben B., Ashok B.S., Masilamoni J.G., Kirubagaran R., Jebaraj W.C.E., Jayakumar R. Anti-inflammatory effect of melatonin on A&#x3b2; vaccination in mice. Mol. Cell. Biochem. 2007;298:69&#x2013;81. doi: 10.1007/s11010-006-9353-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-006-9353-x</ArticleId><ArticleId IdType="pubmed">17136482</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J., Zhang S., Zhao X., Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-&#x3b2;1&#x2013;42. J. Pineal Res. 2008;45:157&#x2013;165. doi: 10.1111/j.1600-079X.2008.00570.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2008.00570.x</ArticleId><ArticleId IdType="pubmed">18298462</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Z., Qin C., Chang Y., Zhang J.T. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer&#x2019;s disease. Free Radic. Biol. Med. 2006;40:101&#x2013;109. doi: 10.1016/j.freeradbiomed.2005.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2005.08.014</ArticleId><ArticleId IdType="pubmed">16337883</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang M.-H., Jung S.-B., Lee M.-H., Kim C.-J., Oh Y.-T., Kang I., Kim J., Kim E.-H. Melatonin attenuates amyloid beta25&#x2013;35-induced apoptosis in mouse microglial BV2 cells. Neurosci. Lett. 2005;380:26&#x2013;31. doi: 10.1016/j.neulet.2005.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.01.003</ArticleId><ArticleId IdType="pubmed">15854745</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragicevic N., Copes N., O&#x2019;Neal-Moffitt G., Jin J., Buzzeo R., Mamcarz M., Tan J., Cao C., Olcese J.M., Arendash G.W., et al. Melatonin treatment restores mitochondrial function in Alzheimer&#x2019;s mice: A mitochondrial protective role of melatonin membrane receptor signaling. J. Pineal Res. 2011;51:75&#x2013;86. doi: 10.1111/j.1600-079X.2011.00864.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2011.00864.x</ArticleId><ArticleId IdType="pubmed">21355879</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Xu G., Duan P., Zhang Q., Wang J. Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol. Sin. 2005;26:519&#x2013;526. doi: 10.1111/j.1745-7254.2005.00102.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1745-7254.2005.00102.x</ArticleId><ArticleId IdType="pubmed">15842767</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebadi M., Sharma S.K., Ghafourifar P., Brown-Borg H., El ReFaey H. Peroxynitrite in the pathogenesis of Parkinson&#x2019;s disease and the neuroprotective role of metallothioneins. Methods Enzymol. 2005;396:276&#x2013;298. doi: 10.1016/S0076-6879(05)96024-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(05)96024-2</ArticleId><ArticleId IdType="pubmed">16291239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetsawang J., Govitrapong P., Chetsawang B. Melatonin inhibits MPP+-induced caspase-mediated death pathway and DNA fragmentation factor-45 cleavage in SK-N-SH cultured cells. J. Pineal Res. 2007;43:115&#x2013;120. doi: 10.1111/j.1600-079X.2007.00449.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2007.00449.x</ArticleId><ArticleId IdType="pubmed">17645689</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvira D., Tajes M., Verdaguer E., Acuna-Castroviejo D., Folch J., Camins A., Pallas M. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson&#x2019;s disease. J. Pineal Res. 2006;40:251&#x2013;258. doi: 10.1111/j.1600-079X.2005.00308.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2005.00308.x</ArticleId><ArticleId IdType="pubmed">16499562</ArticleId></ArticleIdList></Reference><Reference><Citation>Jou M.J., Peng T.I., Reiter R.J., Jou S.-B., Wu H.Y., Wen S.T. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J. Pineal Res. 2004;37:55&#x2013;70. doi: 10.1111/j.1600-079X.2004.00140.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00140.x</ArticleId><ArticleId IdType="pubmed">15230869</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetsawang B., Govitrapong P., Ebadi M. The neuroprotective effect of melatonin against the induction of c-Jun phosphorylation by 6-hydroxydopamine on SK-N-SH cells. Neurosci. Lett. 2004;371:205&#x2013;208. doi: 10.1016/j.neulet.2004.08.068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.08.068</ArticleId><ArticleId IdType="pubmed">15519758</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xfa;nez I., Montilla P., del Carmen Mu&#xf1;oz M., Feij&#xf3;o M., Salcedo M. Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington&#x2019;s disease. J. Pineal Res. 2004;37:252&#x2013;256. doi: 10.1111/j.1600-079X.2004.00163.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-079X.2004.00163.x</ArticleId><ArticleId IdType="pubmed">15485551</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Zhu S., Pei Z., Drozda M., Stavrovskaya I.G., Del Signore S.J., Cormier K., Shimony E.M., Wang H., Ferrante R.J., et al. Inhibitors of cytochrome c release with therapeutic potential for Huntington&#x2019;s disease. J. Neurosci. 2008;28:9473&#x2013;9485. doi: 10.1523/JNEUROSCI.1867-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1867-08.2008</ArticleId><ArticleId IdType="pmc">PMC2632939</ArticleId><ArticleId IdType="pubmed">18799679</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigamonti D., Sipione S., Goffredo D., Zuccato C., Fossale E., Cattaneo E. Huntingtin&#x2019;s Neuroprotective Activity Occurs via Inhibition of Procaspase-9 Processing. J. Biol. Chem. 2001;276:14545&#x2013;14548. doi: 10.1074/jbc.C100044200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C100044200</ArticleId><ArticleId IdType="pubmed">11278258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigamonti D., Bauer J.H., De-Fraja C., Conti L., Sipione S., Sciorati C., Clementi E., Hackam A., Hayden M.R., Li Y., et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J. Neurosci. 2000;20:3705&#x2013;3713. doi: 10.1523/JNEUROSCI.20-10-03705.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-10-03705.2000</ArticleId><ArticleId IdType="pmc">PMC6772672</ArticleId><ArticleId IdType="pubmed">10804212</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X. The antiapoptotic activity of melatonin in neurodegenerative diseases. CNS Neurosci. Ther. 2009;15:345&#x2013;357. doi: 10.1111/j.1755-5949.2009.00105.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2009.00105.x</ArticleId><ArticleId IdType="pmc">PMC2846661</ArticleId><ArticleId IdType="pubmed">19818070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kooncumchoo P., Sharma S., Porter J., Govitrapong P., Ebadi M. Coenzyme Q10 provides neuroprotection in iron-induced apoptosis in dopaminergic neurons. J. Mol. Neurosci. 2006;28:125&#x2013;141. doi: 10.1385/JMN:28:2:125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:28:2:125</ArticleId><ArticleId IdType="pubmed">16679553</ArticleId></ArticleIdList></Reference><Reference><Citation>Shults C.W., Oakes D., Kieburtz K., Flint Beal M., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., et al. Effects of coenzyme Q 10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch. Neurol. 2002;59:1541&#x2013;1550. doi: 10.1001/archneur.59.10.1541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.10.1541</ArticleId><ArticleId IdType="pubmed">12374491</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal L.J., Grundman M., Berg J., Ernstrom K., Margolin R., Pfeiffer E., Weiner M.F., Zamrini E., Thomas R.G. Idebenone treatment fails to slow cognitive decline in Alzheimer&#x2019;s disease. Neurology. 2003;61:1498&#x2013;1502. doi: 10.1212/01.WNL.0000096376.03678.C1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000096376.03678.C1</ArticleId><ArticleId IdType="pubmed">14663031</ArticleId></ArticleIdList></Reference><Reference><Citation>Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov. 2006;5:493&#x2013;506. doi: 10.1038/nrd2060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2060</ArticleId><ArticleId IdType="pubmed">16732220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallas M., Casadesus G., Smith M., Coto-Montes A., Pelegri C., Vilaplana J., Camins A. Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection. Curr. Neurovasc. Res. 2009;6:70&#x2013;81. doi: 10.2174/156720209787466019.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720209787466019</ArticleId><ArticleId IdType="pubmed">19355928</ArticleId></ArticleIdList></Reference><Reference><Citation>Knutson M.D., Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: Effects on aging and age-related diseases. Nutr. Rev. 2008;66:591&#x2013;596. doi: 10.1111/j.1753-4887.2008.00109.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1753-4887.2008.00109.x</ArticleId><ArticleId IdType="pubmed">18826454</ArticleId></ArticleIdList></Reference><Reference><Citation>Orallo F. Trans-Resveratrol: A Magical Elixir of Eternal Youth? Curr. Med. Chem. 2008;15:1887&#x2013;1898. doi: 10.2174/092986708785132951.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986708785132951</ArticleId><ArticleId IdType="pubmed">18691046</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvira D., Yeste-Velasco M., Folch J., Verdaguer E., Canudas A.M., Pall&#xe0;s M., Camins A. Comparative analysis of the effects of resveratrol in two apoptotic models: Inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience. 2007;147:746&#x2013;756. doi: 10.1016/j.neuroscience.2007.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2007.04.029</ArticleId><ArticleId IdType="pubmed">17583434</ArticleId></ArticleIdList></Reference><Reference><Citation>Juki&#x107; I., Kolobari&#x107; N., Stupin A., Mati&#x107; A., Kozina N., Mihaljevi&#x107; Z., Mihalj M., &#x160;u&#x161;njara P., Stupin M., &#x106;uri&#x107; &#x17d;.B., et al. Carnosine, small but mighty&#x2014;Prospect of use as functional ingredient for functional food formulation. Antioxidants. 2021;10:1037. doi: 10.3390/antiox10071037.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10071037</ArticleId><ArticleId IdType="pmc">PMC8300828</ArticleId><ArticleId IdType="pubmed">34203479</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Shi L., Zhang L.R. Neuroprotective effect of carnosine against salsolinol-induced Parkinson&#x2019;s disease. Exp. Ther. Med. 2017;14:664&#x2013;670. doi: 10.3892/etm.2017.4571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2017.4571</ArticleId><ArticleId IdType="pmc">PMC5488497</ArticleId><ArticleId IdType="pubmed">28672983</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldyrev A., Fedorova T., Stepanova M., Dobrotvorskaya I., Kozlova E., Boldanova N., Bagyeva G., Ivanova-Smolenskaya I., Illarioshkin S. Carnisone increases efficiency of DOPA therapy of Parkinson&#x2019;s disease: A pilot study. Rejuvenation Res. 2008;11:821&#x2013;827. doi: 10.1089/rej.2008.0716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/rej.2008.0716</ArticleId><ArticleId IdType="pubmed">18729814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hipkiss A.R. Carnosine, diabetes and Alzheimer&#x2019;s disease. Expert Rev. Neurother. 2009;9:583&#x2013;585. doi: 10.1586/ern.09.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/ern.09.32</ArticleId><ArticleId IdType="pubmed">19402768</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajialyani M., Farzaei M.H., Echeverr&#xed;a J., Nabavi S.M., Uriarte E., Eduardo S.S. Hesperidin as a neuroprotective agent: A review of animal and clinical evidence. Molecules. 2019;24:648. doi: 10.3390/molecules24030648.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24030648</ArticleId><ArticleId IdType="pmc">PMC6384806</ArticleId><ArticleId IdType="pubmed">30759833</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho J. Antioxidant and neuroprotective effects of hesperidin and its aglycone hesperetin. Arch. Pharm. Res. 2006;29:699&#x2013;706. doi: 10.1007/BF02968255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02968255</ArticleId><ArticleId IdType="pubmed">16964766</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemanth Kumar B., Dinesh Kumar B., Diwan P.V. Hesperidin, a citrus flavonoid, protects against l-methionine-induced hyperhomocysteinemia by abrogation of oxidative stress, endothelial dysfunction and neurotoxicity in Wistar rats. Pharm. Biol. 2017;55:146&#x2013;155. doi: 10.1080/13880209.2016.1231695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13880209.2016.1231695</ArticleId><ArticleId IdType="pmc">PMC7011910</ArticleId><ArticleId IdType="pubmed">27677544</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinyor B., Mineo J., Ochner C. Alzheimer&#x2019;s Disease, Inflammation, and the Role of Antioxidants. J. Alzheimer&#x2019;s Dis. Reports. 2020;4:175&#x2013;183. doi: 10.3233/ADR-200171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/ADR-200171</ArticleId><ArticleId IdType="pmc">PMC7369138</ArticleId><ArticleId IdType="pubmed">32715278</ArticleId></ArticleIdList></Reference><Reference><Citation>Veurink G., Perry G., Singh S.K. Role of antioxidants and a nutrient rich diet in Alzheimer&#x2019;s disease. Open Biol. 2020;10:200084. doi: 10.1098/rsob.200084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.200084</ArticleId><ArticleId IdType="pmc">PMC7333894</ArticleId><ArticleId IdType="pubmed">32543351</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y., Feng Q., Kumagai T., Torikai K., Ohigashi H., Osawa T., Noguchi N., Niki E., Uchida K. Ebselen, a glutathione peroxidase mimetic seleno-organic compound, as a multifunctional antioxidant: Implication for inflammation-associated carcinogenesis. J. Biol. Chem. 2002;277:2687&#x2013;2694. doi: 10.1074/jbc.M109641200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109641200</ArticleId><ArticleId IdType="pubmed">11714717</ArticleId></ArticleIdList></Reference><Reference><Citation>Santi C., Scimmi C., Sancineto L. Ebselen and analogues: Pharmacological properties and synthetic strategies for their preparation. Molecules. 2021;26:4230. doi: 10.3390/molecules26144230.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26144230</ArticleId><ArticleId IdType="pmc">PMC8306772</ArticleId><ArticleId IdType="pubmed">34299505</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini F., Rosa S.G., Klann I.P., Fulco B.C.W., Carvalho F.B., Rahmeier F.L., Fernandes M.C., Nogueira C.W. A multifunctional compound ebselen reverses memory impairment, apoptosis and oxidative stress in a mouse model of sporadic Alzheimer&#x2019;s disease. J. Psychiatr. Res. 2019;109:107&#x2013;117. doi: 10.1016/j.jpsychires.2018.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychires.2018.11.021</ArticleId><ArticleId IdType="pubmed">30521994</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Zhu X., Ladenheim B., Yu Q.-S., Guo Z., Oyler J., Cutler R.G., Cadet J.L., Greig N.H., Mattson M.P. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann. Neurol. 2002;52:597&#x2013;606. doi: 10.1002/ana.10350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10350</ArticleId><ArticleId IdType="pubmed">12402257</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves Da Costa C., Paitel E., Mattson M.P., Amson R., Telerman A., Ancolio K., Checler F. Wild-type and mutated presenilins 2 trigger p53-dependent apoptosis and down-regulate presenilin 1 expression in HEK293 human cells and in murine neurons. Proc. Natl. Acad. Sci. USA. 2002;99:4043&#x2013;4048. doi: 10.1073/pnas.062059899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.062059899</ArticleId><ArticleId IdType="pmc">PMC122645</ArticleId><ArticleId IdType="pubmed">11904448</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharpless N.E., DePinho R.A. p53: Good cop/bad cop. Cell. 2002;110:9&#x2013;12. doi: 10.1016/S0092-8674(02)00818-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)00818-8</ArticleId><ArticleId IdType="pubmed">12150992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassi L., Carloni M., Fonti E., Palma De La Pe&#xf1;a N., Meschini R., Palitti F. Pifithrin-&#x3b1;, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Mutat. Res. Fundam. Mol. Mech. Mutagen. 2002;499:163&#x2013;176. doi: 10.1016/S0027-5107(01)00273-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0027-5107(01)00273-1</ArticleId><ArticleId IdType="pubmed">11827710</ArticleId></ArticleIdList></Reference><Reference><Citation>Kakimura J.-I., Kitamura Y., Takata K., Kohno Y., Nomura Y., Taniguchi T. Release and aggregation of cytochrome c and &#x3b1;-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol. 2001;417:59&#x2013;67. doi: 10.1016/S0014-2999(01)00902-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-2999(01)00902-5</ArticleId><ArticleId IdType="pubmed">11301060</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler L., WoldeMussie E., Lai R. Role of alpha-2 agonists in neuroprotection. Surv. Ophthalmol. 2003;48:S47&#x2013;S51. doi: 10.1016/S0039-6257(03)00004-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6257(03)00004-3</ArticleId><ArticleId IdType="pubmed">12852434</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLusky N.J., Chalmers-Redman R., Kay G., Ju W., Nethrapalli I.S., Tatton W.G. Ovarian steroids reduce apoptosis induced by trophic insufficiency in nerve growth factor-differentiated PC12 cells and axotomized rat facial motoneurons. Neuroscience. 2003;118:741&#x2013;754. doi: 10.1016/S0306-4522(02)00940-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(02)00940-5</ArticleId><ArticleId IdType="pubmed">12710981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahlskog J.E. Slowing Parkinson&#x2019;s disease progression: Recent dopamine agonist trials. Neurology. 2003;60:381&#x2013;389. doi: 10.1212/01.WNL.0000044047.58984.2F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000044047.58984.2F</ArticleId><ArticleId IdType="pubmed">12580184</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbimbo B.P. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer&#x2019;s disease. Expert Opin. Investig. Drugs. 2004;13:1469&#x2013;1481. doi: 10.1517/13543784.13.11.1469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543784.13.11.1469</ArticleId><ArticleId IdType="pubmed">15500394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirohata M., Ono K., Naiki H., Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer&#x2019;s &#x3b2;-amyloid fibrils in vitro. Neuropharmacology. 2005;49:1088&#x2013;1099. doi: 10.1016/j.neuropharm.2005.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2005.07.004</ArticleId><ArticleId IdType="pubmed">16125740</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrignani P., Tacconelli S., Sciulli M.G., Capone M.L. New insights into COX-2 biology and inhibition. Brain Res. Rev. 2005;48:352&#x2013;359. doi: 10.1016/j.brainresrev.2004.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresrev.2004.12.024</ArticleId><ArticleId IdType="pubmed">15850674</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dam D., Coen K., De Deyn P.P. Ibuprofen modifies cognitive disease progression in an Alzheimer&#x2019;s mouse model. J. Psychopharmacol. 2010;24:383&#x2013;388. doi: 10.1177/0269881108097630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881108097630</ArticleId><ArticleId IdType="pubmed">18957478</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasqualetti P., Bonomini C., Dal Forno G., Paulon L., Sinforiani E., Marra C., Zanetti O., Rossini P.M. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer&#x2019;s disease. Aging Clin. Exp. Res. 2009;21:102&#x2013;110. doi: 10.1007/BF03325217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03325217</ArticleId><ArticleId IdType="pubmed">19448381</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D.R., Graff-Radford N., May S., Hendrix S., Cottrell B.A., Sagi S.A., Mather G., Laughlin M., Zavitz K.H., Swabb E., et al. Safety, Tolerability, Pharmacokinetics, and A&#x3b2; Levels After Short-term Administration of R-flurbiprofen in Healthy Elderly Individuals. Alzheimer Dis. Assoc. Disord. 2007;21:292&#x2013;299. doi: 10.1097/WAD.0b013e31815d1048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31815d1048</ArticleId><ArticleId IdType="pubmed">18090435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoozemans J., O&#x2019;Banion M. The Role of COX-1 and COX-2 in Alzheimers Disease Pathology and the Therapeutic Potentials of Non-Steroidal Anti-Inflammatory Drugs. Curr. Drug Target-CNS Neurol. Disord. 2005;4:307&#x2013;315. doi: 10.2174/1568007054038201.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568007054038201</ArticleId><ArticleId IdType="pubmed">15975032</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello C.A. Anti-inflammatory Agents: Present and Future. Cell. 2010;140:935&#x2013;950. doi: 10.1016/j.cell.2010.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.02.043</ArticleId><ArticleId IdType="pmc">PMC3752337</ArticleId><ArticleId IdType="pubmed">20303881</ArticleId></ArticleIdList></Reference><Reference><Citation>Minghetti L. Cyclooxygenase-2 (COX-2) in Inflammatory and Degenerative Brain Diseases. J. Neuropathol. Exp. Neurol. 2004;63:901&#x2013;910. doi: 10.1093/jnen/63.9.901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/63.9.901</ArticleId><ArticleId IdType="pubmed">15453089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tatton W., Chen D., Chalmers-Redman R., Wheeler L., Nixon R., Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer&#x2019;s disease: Anti-apoptosis by alpha-2-adrenergic receptor activation. Surv. Ophthalmol. 2003;48:S25&#x2013;S37. doi: 10.1016/S0039-6257(03)00005-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6257(03)00005-5</ArticleId><ArticleId IdType="pubmed">12852432</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldmeier P.C., Tatton W.G. Interrupting apoptosis in neurodegenerative disease: Potential for effective therapy? Drug Discov. Today. 2004;9:210&#x2013;218. doi: 10.1016/S1359-6446(03)03000-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6446(03)03000-9</ArticleId><ArticleId IdType="pubmed">14980539</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T.Q., Song J.N., Zheng F.W., Pang H.G., Zhao Y.L., Gu H., Zhao J.J. Protection of FK506 against neuronal apoptosis and axonal injury following experimental diffuse axonal injury. Mol. Med. Rep. 2017;15:3001&#x2013;3010. doi: 10.3892/mmr.2017.6350.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2017.6350</ArticleId><ArticleId IdType="pmc">PMC5428482</ArticleId><ArticleId IdType="pubmed">28339015</ArticleId></ArticleIdList></Reference><Reference><Citation>Sierra-Paredes G., Sierra-Marcu&#xf1;o G. Ascomycin and FK506: Pharmacology and Therapeutic Potential as Anticonvulsants and Neuroprotectants. CNS Drug Rev. 2008;14:36&#x2013;46. doi: 10.1111/j.1527-3458.2008.00036.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1527-3458.2008.00036.x</ArticleId><ArticleId IdType="pmc">PMC6494028</ArticleId><ArticleId IdType="pubmed">18482098</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y.F., Hayashi Y., Moriwaki A., Tomizawa K., Matsui H. FK506, a Ca2+/calmodulin-dependent phosphatase inhibitor, inhibits the induction of long-term potentiation in the rat hippocampus. Neurosci. Lett. 1996;205:103&#x2013;106. doi: 10.1016/0304-3940(96)12384-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(96)12384-3</ArticleId><ArticleId IdType="pubmed">8907327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura Y., Itano Y., Kubo T., Nomura Y. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J. Neuroimmunol. 1994;50:221&#x2013;224. doi: 10.1016/0165-5728(94)90049-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-5728(94)90049-3</ArticleId><ArticleId IdType="pubmed">7509816</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilho R.F., Hansson O., Brundin P. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. Exp. Neurol. 2000;164:94&#x2013;101. doi: 10.1006/exnr.2000.7405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2000.7405</ArticleId><ArticleId IdType="pubmed">10877919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.H., Won R., Kim U.J., Kim G.M., Chung M.A., Sohn J.H., Lee B.H. Neuroprotective effects of FK506 against excitotoxicity in organotypic hippocampal slice culture. Neurosci. Lett. 2010;474:126&#x2013;130. doi: 10.1016/j.neulet.2010.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.03.009</ArticleId><ArticleId IdType="pubmed">20226231</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Espinosa D., Jennifer Morton A. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington&#x2019;s disease mutation. Brain Res. Bull. 2006;69:669&#x2013;679. doi: 10.1016/j.brainresbull.2006.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2006.03.013</ArticleId><ArticleId IdType="pubmed">16716837</ArticleId></ArticleIdList></Reference><Reference><Citation>Xifr&#xf3; X., Garc&#xed;a-Mart&#xed;nez J.M., del Toro D., Alberch J., P&#xe9;rez-Navarro E. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J. Neurochem. 2008;105:1596&#x2013;1612. doi: 10.1111/j.1471-4159.2008.05252.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2008.05252.x</ArticleId><ArticleId IdType="pubmed">18221365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo R., Colin E., R&#xe9;gulier E., Aebischer P., D&#xe9;glon N., Humbert S., Saudou F. Inhibition of calcineurin by FK506 protects against polyglutamine- huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 2006;26:1635&#x2013;1645. doi: 10.1523/JNEUROSCI.3706-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3706-05.2006</ArticleId><ArticleId IdType="pmc">PMC6675484</ArticleId><ArticleId IdType="pubmed">16452687</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda J.R., Pardo R., Zala D., Yu H., Humbert S., Saudou F. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington&#x2019;s disease. Mol. Brain. 2009;2:33. doi: 10.1186/1756-6606-2-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-2-33</ArticleId><ArticleId IdType="pmc">PMC2776580</ArticleId><ArticleId IdType="pubmed">19860865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar P., Kumar A. Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: Possible role of nitric oxide. Neurosci. Res. 2009;63:302&#x2013;314. doi: 10.1016/j.neures.2009.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2009.01.005</ArticleId><ArticleId IdType="pubmed">19367792</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan W.S., Durairajan S.S.K., Lu J.H., Wang Y., Xie L.X., Kum W.F., Koo I., Yung K.K.L., Li M. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem. Int. 2009;55:414&#x2013;422. doi: 10.1016/j.neuint.2009.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2009.04.012</ArticleId><ArticleId IdType="pubmed">19409437</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdaguer E., Jim&#xe9;nez A., Canudas A.M., Jord&#xe0; E.G., Sureda F.X., Pall&#xe0;s M., Camins A. Inhibition of Cell Cycle Pathway by Flavopiridol Promotes Survival of Cerebellar Granule Cells after an Excitotoxic Treatment. J. Pharmacol. Exp. Ther. 2004;308:609&#x2013;616. doi: 10.1124/jpet.103.057497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.103.057497</ArticleId><ArticleId IdType="pubmed">14610234</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko T., Chaussepied M., Oren M., Ginsberg D. Novel link between E2F and p53: Proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ. 2005;12:377&#x2013;383. doi: 10.1038/sj.cdd.4401575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4401575</ArticleId><ArticleId IdType="pubmed">15706352</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrup K., Arendt T. Re-expression of cell cycle proteins induces neuronal cell death during Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. 2002;4:243&#x2013;247. doi: 10.3233/JAD-2002-4315.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2002-4315</ArticleId><ArticleId IdType="pubmed">12226544</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens C., La Thangue N.B. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair. 2004;3:1071&#x2013;1079. doi: 10.1016/j.dnarep.2004.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dnarep.2004.03.034</ArticleId><ArticleId IdType="pubmed">15279795</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas S.C., Liu D.X., Greene L.A. Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J. Neurosci. 2005;25:8349&#x2013;8358. doi: 10.1523/JNEUROSCI.1570-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1570-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725681</ArticleId><ArticleId IdType="pubmed">16162916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hershko T., Ginsberg D. Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis. J. Biol. Chem. 2004;279:8627&#x2013;8634. doi: 10.1074/jbc.M312866200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M312866200</ArticleId><ArticleId IdType="pubmed">14684737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuello A.C., Bruno M.A., Allard S., Leon W., Iulita M.F. Cholinergic involvement in alzheimer&#x2019;s disease. A link with NGF maturation and degradation. J. Mol. Neurosci. 2010;40:230&#x2013;235. doi: 10.1007/s12031-009-9238-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-009-9238-z</ArticleId><ArticleId IdType="pubmed">19680822</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop K.M., Hofer E.K., Mehta A., Ramirez A., Sun L., Tuszynski M., Bartus R.T. Therapeutic potential of CERE-110 (AAV2-NGF): Targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp. Neurol. 2008;211:574&#x2013;584. doi: 10.1016/j.expneurol.2008.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.03.004</ArticleId><ArticleId IdType="pmc">PMC2709503</ArticleId><ArticleId IdType="pubmed">18439998</ArticleId></ArticleIdList></Reference><Reference><Citation>Baquet Z.C., Bickford P.C., Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J. Neurosci. 2005;25:6251&#x2013;6259. doi: 10.1523/JNEUROSCI.4601-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4601-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725062</ArticleId><ArticleId IdType="pubmed">15987955</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou S.-H., Cui Y., Huang S.-M., Zhang B. The Role of Brain-Derived Neurotrophic Factor Signaling in Central Nervous System Disease Pathogenesis. Front. Hum. Neurosci. 2022;16:394. doi: 10.3389/fnhum.2022.924155.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnhum.2022.924155</ArticleId><ArticleId IdType="pmc">PMC9263365</ArticleId><ArticleId IdType="pubmed">35814950</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda M., Morici J.F., Zanoni M.B., Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Front. Cell. Neurosci. 2019;13:363. doi: 10.3389/fncel.2019.00363.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00363</ArticleId><ArticleId IdType="pmc">PMC6692714</ArticleId><ArticleId IdType="pubmed">31440144</ArticleId></ArticleIdList></Reference><Reference><Citation>Massa S.M., Yang T., Xie Y., Shi J., Bilgen M., Joyce J.N., Nehama D., Rajadas J., Longo F.M. Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J. Clin. Investig. 2010;120:1774&#x2013;1785. doi: 10.1172/JCI41356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI41356</ArticleId><ArticleId IdType="pmc">PMC2860903</ArticleId><ArticleId IdType="pubmed">20407211</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons D.A., Belichenko N.P., Yang T., Condon C., Monbureau M., Shamloo M., Jing D., Massa S.M., Longo F.M. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of huntington&#x2019;s disease. J. Neurosci. 2013;33:18712&#x2013;18727. doi: 10.1523/JNEUROSCI.1310-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1310-13.2013</ArticleId><ArticleId IdType="pmc">PMC3841443</ArticleId><ArticleId IdType="pubmed">24285878</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons D.A. Modulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington&#x2019;s Disease. J. Huntingtons Dis. 2017;6:303&#x2013;325. doi: 10.3233/JHD-170275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JHD-170275</ArticleId><ArticleId IdType="pmc">PMC5757655</ArticleId><ArticleId IdType="pubmed">29254102</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazim S.F., Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: Emerging therapeutic modality for Alzheimer&#x2019;s disease. Mol. Neurodegener. 2016;11:1&#x2013;16. doi: 10.1186/s13024-016-0119-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0119-y</ArticleId><ArticleId IdType="pmc">PMC4940708</ArticleId><ArticleId IdType="pubmed">27400746</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung J.H., Seo A.Y., Chung S.W., Kim M.K., Leeuwenburgh C., Yu B.P., Chung H.Y. Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res. Rev. 2008;7:126&#x2013;136. doi: 10.1016/j.arr.2008.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2008.01.001</ArticleId><ArticleId IdType="pubmed">18313368</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolakakis N., Hamel E. The nuclear receptor PPAR&#x3b3; as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer&#x2019;s disease. Front. Aging Neurosci. 2010;2:21. doi: 10.3389/fnagi.2010.00021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2010.00021</ArticleId><ArticleId IdType="pmc">PMC2912024</ArticleId><ArticleId IdType="pubmed">20725514</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold M., Alderton C., Zvartau-Hind M., Egginton S., Saunders A.M., Irizarry M., Craft S., Landreth G., Linnam&#xe4;gi &#xdc;., Sawchak S. Rosiglitazone monotherapy in mild-to-moderate alzheimer&#x2019;s disease: Results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 2010;30:131&#x2013;146. doi: 10.1159/000318845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000318845</ArticleId><ArticleId IdType="pmc">PMC3214882</ArticleId><ArticleId IdType="pubmed">20733306</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y., Ma D., Xu W., Shao S., Yu X. Effect and cardiovascular safety of adding rosiglitazone to insulin therapy in type 2 diabetes: A meta-analysis. J. Diabetes Investig. 2015;6:78&#x2013;86. doi: 10.1111/jdi.12246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.12246</ArticleId><ArticleId IdType="pmc">PMC4296706</ArticleId><ArticleId IdType="pubmed">25621136</ArticleId></ArticleIdList></Reference><Reference><Citation>Escribano L., Sim&#xf3;n A.M., Gimeno E., Cuadrado-Tejedor M., De Maturana R.L., Garc&#xed;a-Osta A., Ricobaraza A., P&#xe9;rez-Mediavilla A., Del R&#xed;o J., Frechilla D. Rosiglitazone rescues memory impairment in Alzheimer&#x2019;s transgenic mice: Mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology. 2010;35:1593&#x2013;1604. doi: 10.1038/npp.2010.32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2010.32</ArticleId><ArticleId IdType="pmc">PMC3055461</ArticleId><ArticleId IdType="pubmed">20336061</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;sel J., Gandor F., Harms C., Synowitz M., Harms U., Djoufack P.C., Megow D., Dirnagl U., H&#xf6;rtnagl H., Fink K.B., et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J. Neurochem. 2005;92:1386&#x2013;1398. doi: 10.1111/j.1471-4159.2004.02980.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02980.x</ArticleId><ArticleId IdType="pubmed">15748157</ArticleId></ArticleIdList></Reference><Reference><Citation>Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 2000;356:1627&#x2013;1631. doi: 10.1016/S0140-6736(00)03155-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)03155-X</ArticleId><ArticleId IdType="pubmed">11089820</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Toro D., Xifr&#xf3; X., Pol A., Humbert S., Saudou F., Canals J.M., Alberch J. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington&#x2019;s disease. J. Neurochem. 2010;115:153&#x2013;167. doi: 10.1111/j.1471-4159.2010.06912.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06912.x</ArticleId><ArticleId IdType="pubmed">20663016</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon A., K&#xe5;reholt I., Ngandu T., Wolozin B., MacDonald S.W.S., Winblad B., Nissinen A., Tuomilehto J., Soininen H., Kivipelto M. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol. Aging. 2009;30:1006&#x2013;1009. doi: 10.1016/j.neurobiolaging.2007.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.09.012</ArticleId><ArticleId IdType="pubmed">18022292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma T., Zhao Y.B., Kwak Y.D., Yang Z., Thompson R., Luo Z., Xu H., Liao F.F. Statin&#x2019;s excitoprotection is mediated by sAPP and the subsequent attenuation of calpain-induced truncation events, likely via Rho-ROCK signaling. J. Neurosci. 2009;29:11226&#x2013;11236. doi: 10.1523/JNEUROSCI.6150-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6150-08.2009</ArticleId><ArticleId IdType="pmc">PMC2757921</ArticleId><ArticleId IdType="pubmed">19741129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolga A.M., Granic I., Nijholt I.M., Nyakas C., Van Der Zee E.A., Luiten P.G.M., Eisel U.L.M. Pretreatment with lovastatin prevents n-methyl-d-aspartate-induced neurodegeneration in the magnocellular nucleus basalis and behavioral dysfunction. J. Alzheimer&#x2019;s Dis. 2009;17:327&#x2013;336. doi: 10.3233/JAD-2009-1052.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1052</ArticleId><ArticleId IdType="pubmed">19363269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponce J., De La Ossa N.P., Hurtado O., Millan M., Arenillas J.F., D&#xe1;valos A., Gasull T. Simvastatin reduces the association of NMDA receptors to lipid rafts: A cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269&#x2013;1275. doi: 10.1161/STROKEAHA.107.498923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.107.498923</ArticleId><ArticleId IdType="pubmed">18323503</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrandell-Haro G., Branigan G.L., Vitali F., Geifman N., Zissimopoulos J.M., Brinton R.D. Statin therapy and risk of Alzheimer&#x2019;s and age-related neurodegenerative diseases. Alzheimer&#x2019;s Dement. Transl. Res. Clin. Interv. 2020;6:e12108. doi: 10.1002/trc2.12108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/trc2.12108</ArticleId><ArticleId IdType="pmc">PMC7687291</ArticleId><ArticleId IdType="pubmed">33283039</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000;57:1439&#x2013;1443. doi: 10.1001/archneur.57.10.1439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.57.10.1439</ArticleId><ArticleId IdType="pubmed">11030795</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacco A., Togo J., Spence K., Ellis A., Lloyd D., Furlong S., Piser T. 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity. J. Neurosci. 2003;23:11104&#x2013;11111. doi: 10.1523/JNEUROSCI.23-35-11104.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-35-11104.2003</ArticleId><ArticleId IdType="pmc">PMC6741057</ArticleId><ArticleId IdType="pubmed">14657168</ArticleId></ArticleIdList></Reference><Reference><Citation>Koob A.O., Ubhi K., Paulsson J.F., Kelly J., Rockenstein E., Mante M., Adame A., Masliah E. Lovastatin ameliorates &#x3b1;-synuclein accumulation and oxidation in transgenic mouse models of &#x3b1;-synucleinopathies. Exp. Neurol. 2010;221:267&#x2013;274. doi: 10.1016/j.expneurol.2009.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2009.11.015</ArticleId><ArticleId IdType="pmc">PMC2812599</ArticleId><ArticleId IdType="pubmed">19944097</ArticleId></ArticleIdList></Reference><Reference><Citation>Toft S&#xf8;rensen H., Lash T.L. Statins and amyotrophic lateral sclerosis&#x2014;The level of evidence for an association. J. Intern. Med. 2009;266:520&#x2013;526. doi: 10.1111/j.1365-2796.2009.02173.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2009.02173.x</ArticleId><ArticleId IdType="pubmed">19930099</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellner J., Weber M.S., Vollmar P., Mattle H.P., Hemmer B., St&#xfc;ve O. The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: Enthusiasm lost too soon? CNS Neurosci. Ther. 2010;16:362&#x2013;373. doi: 10.1111/j.1755-5949.2010.00179.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2010.00179.x</ArticleId><ArticleId IdType="pmc">PMC6493882</ArticleId><ArticleId IdType="pubmed">20626428</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamvil S.S., Steinman L. Combining statins with interferon beta in multiple sclerosis: Think twice, it might not be all right. Lancet Neurol. 2011;10:672&#x2013;673. doi: 10.1016/S1474-4422(11)70153-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(11)70153-3</ArticleId><ArticleId IdType="pmc">PMC4106800</ArticleId><ArticleId IdType="pubmed">21742557</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul F., Waiczies S., Wuerfel J., Bellmann-Strobl J., D&#xf6;rr J., Waiczies H., Haertle M., Wernecke K.D., Volk H.-D., Aktas O., et al. Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. PLoS ONE. 2008;3:e1928. doi: 10.1371/journal.pone.0001928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001928</ArticleId><ArticleId IdType="pmc">PMC2276246</ArticleId><ArticleId IdType="pubmed">18398457</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V.K., Beattie L.A., Seed T.M. Vitamin E: Tocopherols and tocotrienols as potential radiation countermeasures. J. Radiat. Res. 2013;54:973&#x2013;988. doi: 10.1093/jrr/rrt048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jrr/rrt048</ArticleId><ArticleId IdType="pmc">PMC3823775</ArticleId><ArticleId IdType="pubmed">23658414</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeli J.P.F., Shah R., Pratt D.A., Conrad M. Ferroptosis Inhibition: Mechanisms and Opportunities. Trends Pharmacol. Sci. 2017;38:489&#x2013;498. doi: 10.1016/j.tips.2017.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2017.02.005</ArticleId><ArticleId IdType="pubmed">28363764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zilka O., Shah R., Li B., Friedmann Angeli J.P., Griesser M., Conrad M., Pratt D.A. On the Mechanism of Cytoprotection by Ferrostatin-1 and Liproxstatin-1 and the Role of Lipid Peroxidation in Ferroptotic Cell Death. ACS Cent. Sci. 2017;3:232&#x2013;243. doi: 10.1021/acscentsci.7b00028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.7b00028</ArticleId><ArticleId IdType="pmc">PMC5364454</ArticleId><ArticleId IdType="pubmed">28386601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinman A., Holst C.R., Latham J.C., Bruegger J.J., Ulas G., McCusker K.P., Amagata A., Davis D., Hoff K.G., Kahn-Kirby A.H., et al. Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase. PLoS ONE. 2018;13:e0201369. doi: 10.1371/journal.pone.0201369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0201369</ArticleId><ArticleId IdType="pmc">PMC6093661</ArticleId><ArticleId IdType="pubmed">30110365</ArticleId></ArticleIdList></Reference><Reference><Citation>Conrad M., Proneth B. Selenium: Tracing Another Essential Element of Ferroptotic Cell Death. Cell Chem. Biol. 2020;27:409&#x2013;419. doi: 10.1016/j.chembiol.2020.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2020.03.012</ArticleId><ArticleId IdType="pubmed">32275866</ArticleId></ArticleIdList></Reference><Reference><Citation>Alim I., Caulfield J.T., Chen Y., Swarup V., Geschwind D.H., Ivanova E., Seravalli J., Ai Y., Sansing L.H., Emma E.J., et al. Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke. Cell. 2019;177:1262&#x2013;1279.e25. doi: 10.1016/j.cell.2019.03.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.03.032</ArticleId><ArticleId IdType="pubmed">31056284</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingold I., Berndt C., Schmitt S., Doll S., Poschmann G., Buday K., Roveri A., Peng X., Porto Freitas F., Seibt T., et al. Selenium Utilization by GPX4 Is Required to Prevent Hydroperoxide-Induced Ferroptosis. Cell. 2018;172:409&#x2013;422.e21. doi: 10.1016/j.cell.2017.11.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.11.048</ArticleId><ArticleId IdType="pubmed">29290465</ArticleId></ArticleIdList></Reference><Reference><Citation>Faria M., Prats E., G&#xf3;mez-Canela C., Hsu C.Y., Arick M.A., Bedrossiantz J., Orozco M., Garcia-Reyero N., Ziv T., Ben-Lulu S., et al. Therapeutic potential of N-acetylcysteine in acrylamide acute neurotoxicity in adult zebrafish. Sci. Rep. 2019;9:1&#x2013;11. doi: 10.1038/s41598-019-53154-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-53154-w</ArticleId><ArticleId IdType="pmc">PMC6848153</ArticleId><ArticleId IdType="pubmed">31712630</ArticleId></ArticleIdList></Reference><Reference><Citation>Hara Y., Fillit H.M., Dacks P.A., McKeehan N. Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia. J. Prev. Alzheimer&#x2019;s Dis. 2017;4:1&#x2013;6. doi: 10.14283/jpad.2017.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.14283/jpad.2017.22</ArticleId><ArticleId IdType="pubmed">29182711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu A.L., Dong Z.H., Sun M.J. Protective effect of N-acetyl-l-cysteine on amyloid &#x3b2;-peptide-induced learning and memory deficits in mice. Brain Res. 2006;1109:201&#x2013;206. doi: 10.1016/j.brainres.2006.06.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2006.06.042</ArticleId><ArticleId IdType="pubmed">16872586</ArticleId></ArticleIdList></Reference><Reference><Citation>Karuppagounder S.S., Alin L., Chen Y., Brand D., Bourassa M.W., Dietrich K., Wilkinson C.M., Nadeau C.A., Kumar A., Perry S., et al. N-Acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E2 to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice. Ann. Neurol. 2018;84:854&#x2013;872. doi: 10.1002/ana.25356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25356</ArticleId><ArticleId IdType="pmc">PMC6519209</ArticleId><ArticleId IdType="pubmed">30294906</ArticleId></ArticleIdList></Reference><Reference><Citation>Camins A., Pall&#xe0;s M., Silvestre J.S. Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches. Methods Find. Exp. Clin. Pharmacol. 2008;30:43. doi: 10.1358/mf.2008.30.1.1090962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/mf.2008.30.1.1090962</ArticleId><ArticleId IdType="pubmed">18389097</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>